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Abstract in English 
Rotavirus infects nearly every child by the age of 3–5 years and is the leading cause 
of severe, dehydrating diarrhea in children aged <5 years worldwide. In Vietnam, nearly 
haft of diarrhea-related deaths are accounted for Rotavirus; the country also had one of the 
highest Rotavirus hospitalization figures in South East Asia. The two Rotavirus vaccines 
(Rotarix and Rotateq) were licensed in the state and available in the private sector, as well 
as Rotavin-M1 - a local licensed vaccine. In 1998, the Rotavirus sentinel surveillance was 
initiated in Vietnam. This study aimed to describe the Rotavirus sentinel surveillance 
findings from 2013 to 2018, including epics profile, clinical features, and genotyping 
information among hospitalized children under five years of age. Methods: A hospital-
based study was performed from the Rotavirus sentinel surveillance at Paediatric Hospital 
No.1 in Ho Chi Minh city, Vietnam. Data were collected from children between 0 and 59 
months of age whose primary reason for hospitalization was acute watery diarrhea. 
Children were included in the vaccine effectiveness  analysis (VE) if they were at least six 
months old at the time of notification. Results: During 2013-2018, of 5,179 acute diarrhea 
cases included in the study, Rotavirus was detected in 2,424 cases (46.80%), a downward 
trend was observed from 2013 (55.27%) to 2018 (43.54%). Dry season months (from 
November to April) witnessed a 2.4 times higher occurrence of  Rotavirus positive cases 
compared to rainy season months (May to October) (OR=2.4, 95% CI: 2.14 - 2.692, 
p<0.001). The mortality rate was 0.04%. The typical symptoms associated with Rotavirus 
AGE were vomiting (present of vomiting, average max number per day, duration), 
dehydration status, present of fever, diarrhea (average max number per day) (p<0.05). 
Rotavirus AGE was more likely to be severe than the negative group (p<0.001). Of 1,107 
Rotavirus positive cases had PCR isolated for genotyping, G3P[8] was the most common 
G-P combined genotype (43.18%), followed by G8P[8], G1P[8], G2P[4] (constituted 
19.69%, 12.92%, and 12.83%, respectively). We observed an enormous genotyping shift 
from 2013 to 2018: G3P[8] became more frequent during 2014-2018, with the rise from 
8.13% in 2013 to a peak of 60.65% in 2017, then decreased to 41.15% in 2018. In contrast, 
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G1P[8] considerably dropped from 69.92% in 2013 to no case in 2018. There also occurred 
a change in G8P[8] and G2P[4] prevalence. From no case in 2013, G8P[8] leaped to a peak 
of 47.21% in 2016 and was the predominant genotype at that year, before went down to 
23.92% in 2018. G2P[4] showed a slight upward trend from 2013 to 2014 (from 15.45% 
to 37.41%), then dropped to 0.43% in 2016, before went up to 16.27% in 2018. The 
percentage of vaccinees among the study population was meager (3.84%). Among children 
≥ 6 months of age, getting a completed schedule of Rotavirus vaccine in general, and the 
Rotarix vaccine in particular, had vaccine effectiveness against Rotavirus AGE at 82.34% 
(95% CI: 70.33%-89.49%), and 85.90% (95% CI: 74.10%-92.30%), respectively. Rotarix 
VE for G3P[8] was 88.35% (95% CI: 52.50%-97.14%). Conclusions: The findings in our 
study suggested that Rotavirus infection was still a significant cause of acute watery 
diarrhea among hospitalized children younger than five years old in Vietnam. There is a 
need to consider the recommended vaccine to use in the National Immunization Program 
in the dramatic genotyping shift situation. In addition to monitoring genotypes, whole 
genomic characterization of circulating Rotavirus strains before and after vaccine 









Rotavirus infects nearly every child by the age of 3–5 years and is the leading cause 
of severe, dehydrating diarrhea in children under five years old worldwide. In low-income 
countries, the median age at the primary Rotavirus infection ranges from six to nine months 
(80% in infants less than one year of age) whereas in high-income countries, the first 
episode may be delayed until 2–5 years old, though the majority still happen in infancy 
(65% in infants under one year old) [1]. 
Estimates from 2013 determined that Vietnam had a total of 2,083 diarrhea-related 
deaths, of which 49.9% were due to Rotavirus. Rotavirus accounted for 3.1% total death 
of children under five years old [2]. The country also had one of the highest Rotavirus 
hospitalization figures in South East Asia [3]. 
In 1998, Vietnam launched Rotavirus surveillance under the auspices of the World 
Health Organization (WHO). During the period 2012–2015, a total of 8,889 children under 
five years of age were enrolled in the surveillance, in which Rotavirus was the most 
common pathogen (46.7%). A downtrend of G1P[8] prevalence was observed [4]. 
Rotavirus disease burden in Vietnam was estimated at approximately $3.1 million 
in direct medical costs, $685,000 in direct non-medical costs, and $1.5 million in indirect 
costs (Fischer et al., 2004) [5].  In 2009, data were collected from hospitalized children 
under five years old with symptoms of acute gastroenteritis (AGE) evaluated that costs of 
Rota-positive patients and Rota-negative patients were $217 and $158, respectively [6].  
Vaccination offers the best protection for infants against severe diarrhea and death 
from Rotavirus infection, WHO recommends the routine use of Rotavirus vaccine in 




2018. Global coverage was estimated at 35% [7]. 
In Vietnam, there are two WHO pre-qualified available (Rotarix and Rotateq), 
together with Rotavin-M1 - a local licensed vaccine manufactured by state-owned 
company POLYVAC (Center for Research and Production of Vaccines and Biologicals). 
The price of this Vietnamese-made vaccine is one-third the cost of an imported vaccine, at 
just $15 per dose. The second generation of Rotavin-M1 is evaluated on a clinical trial 
named Rotavin. The new vaccine is produced in the same way with Rotavin-M1 but more 
compatible with the cold chain currently in place in Vietnam, allowing for more accessible 
storage and transport [8]. 
Considering that Vietnam will introduce Rotavirus vaccines to the Expanded 
Program on Immunization soon, it is crucial and necessary to understand the epidemiology 
and genotyping diversity in pre-routine Rotavirus vaccines era. The disease surveillance 
system is one of the vital roles to provide this information supporting vaccine introduction 
decisions. Being a part of the National System, the Pasteur Institute in Ho Chi Minh City 
has been responsible for Rotavirus sentinel surveillance in Southern Vietnam, in 
coordinating with Children Hospital No. 1 in Ho Chi Minh City since 1998. 
This study aimed to describe the Rotavirus sentinel surveillance findings from 
2013 to 2018, including epics profile, clinical features, and genotyping information among 







1.2.1. Research questions 
What is the epidemiology of Rotavirus acute gastroenteritis (AGE) and genetic 
characteristics of the strains circulating in Southern Vietnam?   
1.2.2. Objectives 
- General Objectives: 
To determine the Rotavirus disease epics profile, genotyping information among 
children under five years of age in Southern Vietnam from 2013 to 2018. 
- Specific Objectives: 
+ To determine the prevalence, age, and geographic distribution, seasonality of 
Rotavirus disease among children aged <5 years in Southern Vietnam from 2013 to 2018. 	
+ To determine the clinical features of Rotavirus disease among children aged <5 
years in Southern Vietnam from 2015 to 2018.  	
+ To determine the genotypic diversity of Rotavirus strains detected in children 
aged <5 years in Southern Vietnam from 2013-2018. 
+ To determine the Rotavirus vaccine effectiveness in hospitalized children aged 







2.1. VIROLOGY OF ROTAVIRUS 
2.1.1. History of the virus 
Rotavirus is a virus that causes infection in the intestine. At the beginning of the 
1970s, scientists who study bacteria, viruses, or parasites could only identify less than 30% 
of the number of diarrheal case in children. In 1973, thanks to an electron micrograph, 
Bishop and his colleagues successfully observed a virus particle in the intestinal tissue of 
diarrheal children [9]. In the same year, the name Rotavirus was suggested for its 
appearance under a microscope like a wheel, which means “Rota” in Latin [10]. 
2.1.2. Structure 
As a genus of Reoviridae, the structure of Rotavirus consists of segmented viruses 
and double-stranded RNA genomes. Rotavirus has a massive particle that contains the viral 
genome of 11 of double-stranded RNA surrounded by a triple-layered protein capsid (an 
outer, inner capsid, and a core). Virus particle (viral protein [VPs]) is made up of 6 
structural proteins and six nonstructural proteins. Only segment 11, which contains 
information for NSP5 and NSP6, encodes a single protein [11], [12]. 
Found in the internal capsid, VP6, which carries group-specific epitopes, is 
considered as the most highly represented structural protein [12], [13]. While three 
structural proteins (VP1, VP2, and VP3) and six nonstructural proteins (NSP1, NSP2, 
NSP3, NSP4, NSP5, and NSP6) create the core of the virus, NSP4 creates a harmful 
substance for digestive system which called enterotoxin [11], [12], [14]. 
Forming the outer capsid shell and creating spikes that release through the outer 
capsid shell are respectively distinct functions of VP4 and VP7, which induce neutralizing 





Figure 2.1. Schematic diagram and electron micrograph of Rotavirus particles. 
Source: [11]. 
A: The particle is composed of three concentric protein shells (VP7, VP6, and VP2, 
shown in different colors) and the spike protein VP4 that spans the VP6 and VP7 
layers and extends out from the particle. A transcription complex of VP1 and VP3 
is inside the VP2 layer. The viral double-stranded RNA (dsRNA) genome is 
segmented. 
B: Rotavirus triple-layered particles and a few double-layered particles (arrows) are 





Figure 2.2. Rotavirus structures [15], [16]. 
 






Figure 2.4. Model of Rotavirus-induced 
diarrhea. 
Panel A depicts events in the 
infected epithelium (from left to right across 
the four cells). 
Panel B shows the typical 
architecture of the small intestine, with the 
circulatory system removed for clarity. This 
panel emphasizes the ENS and its ganglia in 
the different submucosal levels [17], [18]. 
Panel C shows a reflex arc in the 
ENS that can receive signals from the villus 
epithelium and activate the crypt epithelium. 
Inset 1 shows a whole mount of an adult 
mouse small intestinal villus, stained with 
antibody to protein gene product 9.5 to 
reveal the rich innervation (yellow stain). 
Inset 2 shows that infected villus enterocytes 
may stimulate the ENS by the basolateral 




Figure 2.3 shows a schematic of the Rotavirus replication cycle. To summarize, 
the Rotavirus replication cycle includes the following steps: 
- Attachment, mediated by VP4 and VP7; 
- Penetration and uncoating; 
- Plus strand ssRNA (=mRNA) synthesis, mediated by VP1, VP3 and VP2; 
- Viroplasm formation, mediating RNA packaging, minus-strand RNA synthesis 
(=RNA replication) and DLP formation; 
- Virus particle maturation (to TLPs) and release. 
2.1.4. Classification 
According to the serological reactivity and genetic variability of VP6, at least eight 
different groups, also termed species, are differentiated (termed RVA-RVH). The 
Rotavirus species comprises at least 36 G types (according to the nt sequence of VP7) and 
51 P types (according to the nt sequence of VP4) [15], [19], [20]. 
- For G types, serotypes and genotypes are synonymous, for example, G1, G2. 
- For P types, there are many more P genotypes than reference sera determining P 
serotypes: therefore, a double nomenclature has been introduced, for example, 
P1A[8] designating the P serotype 1A and P genotype 8 [11]. 
Table 2.1.  Genotypes of species A Rotaviruses. 
Rotavirus protein Percent identity Number of 
genotypes 
Genotype 
VP7 80 27G Glycosylated 
VP4 80 35P Protease sensitive  
VP6 85 16I Inner capsid 
VP1 83 9R RdRpc 
VP2 84 9C Core protein 
VP3 81 8M Methyltransferase 
NSP1 79 16A Interferon Antagonist 
NSP2 85 9N NTPase  
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Rotavirus protein Percent identity Number of 
genotypes 
Genotype 
NSP3 85 12T Translation enhancer 
NSP4 85 14E Enterotoxin 
NSP5 91 11H PHosphoprotein  
Source: [11], [21]. 
2.1.5. Genotypes 
Currently, 36 G and 51 P genotypes have been approved by the Rotavirus 
Classification Working Group [20]. A complete Rotavirus serotype is described using a 
number (or a number and letter) for the P serotype, followed by a number in brackets that 
represent the P genotype. It is followed or preceded by the G type designation (e.g., 
P1A[8]G1). Table 2 lists the most common human serotypes [12]. 
Table 2.2. Common Human Group A Rotavirus Serotypes Worldwide  
VP4 Serotype (Genotypes)  Associated VP7 Types  
P1A[8] G1, G3, G4, G9, G12 
P1P1B[4] G2 
P2[6] G9, G12 
Source: [12]. 
2.2. PATHOGENESIS 
The mechanism by which Rotavirus induces diarrhea is poorly understood. The 
available reports describe various findings: malabsorption following the destruction of the 
epithelium [22], villus ischemia [23], the action of NSP4, a viral enterotoxin [24], and 
activation of the enteric nervous system [25]. Recently, the pathogenesis of the symptom 
vomiting has also been elucidated by observations that Rotavirus can infect the 
enterochromaffin cells in the gut and stimulate the production of 5- hydroxytryptamine 
(serotonin) which in turn activates vagal afferent nerves and stimulates brain stem 




Rotavirus infections are more likely to be severe in children three to 24 months 
of age than in younger infants or older children and adults. Several studies have offered 
possible explanations for these differences in age susceptibility. First, children of 
increasing age may be protected by a virus-specific immune response generated by 
repeated natural infections. Protection of young infants may be mediated by passively 
transferred, transplacental, maternal antibodies. Breastfeeding protects against Rotavirus 
disease. Second, infant mice have a larger percentage of intestinal epithelial cells with 
putative Rotavirus-binding proteins on the surface than do older mice - an observation that 
correlates directly with the age susceptibility to disease. Last, Rotavirus entry into target 
cells is facilitated by cleavage of VP4, which occurs in the presence of trypsin, elastase, or 
pancreatin. Quantities of these exopeptidases are decreased in intestinal fluid secretions of 
newborn infants compared with older infants and young children [12]. 
Children in developing countries are more susceptible to severe Rotavirus disease 
than those in developed countries. This is probably a consequence of poor access to 
hydration therapy and medical care, poor nutrition, concomitant infections, and possible 
differences in the gut microbiome [27].  Several studies in animals support the hypotheses 
that poor nutrition, or associated bacterial infections, may enhance the severity of 
Rotavirus-induced enteritis [12].
2.3. IMMUNITY AND PROTECTION 
Protection against Rotavirus infection is mediated by both humoral and cellular 
components of the immune system. Following the first infection, the serological response 
is directed mainly against the specific viral serotype (for example, a homotypic response), 
whereas a broader, heterotypic antibody response is elicited following ≥1 subsequent 
Rotavirus infections [28]. 
A study that monitored 200 Mexican infants from birth to two years of age by 
weekly home visits and stool collections detected based on the fecal excretion of virus or 
a serologic response a total of 316 Rotavirus infections, of which 52% were first and 48% 
repeated infections. Children with 1, 2, or 3 previous infections had a progressively lower 
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risk of subsequent Rotavirus infection (adjusted relative risk, 0.62, 0.40, and 0.34, 
respectively) or diarrhea (adjusted relative risk, 0.23, 0.17, and 0.08) than children who had 
no previous infections. Subsequent infections were significantly less severe than first 
infections (p=0.02), and second infections were more likely to be caused by another G type 
(p=0.05) [29]. However, one study from India reported that the risk of severe disease 
continued after several reinfections [30]. 
Rotavirus is a ubiquitous infection in young children. In settings without Rotavirus 
vaccines, nearly all children are exposed to Rotavirus and acquire antibodies by 2 to 3 years 
of age, and most Rotavirus diarrhea occurs during the first three years. In the first three 
months, infections might be asymptomatic or less severe than those in older infants; this is 
most likely a result of the protective effect of passively transferred maternal antibodies or 
breastfeeding or both. Infections in neonatal nurseries are often asymptomatic. First 
infections after three months of age are generally associated with diarrhea that can range 
from mild to severe, whereas subsequent exposures lead to milder illness or asymptomatic 
infections  [12]. 
2.4. CLINICAL MANIFESTATION, DIAGNOSIS 
2.4.1. Clinical manifestation 
In children, the incubation period for Rotavirus diarrhea is short, usually less than 
48 hours. The clinical manifestations of infection vary and depend on whether it is the first 
infection or reinfection. The first infection after three months of age is generally the most 
severe. Infection may be asymptomatic, may cause self-limited watery diarrhea, or may 
result in severe dehydrating diarrhea with fever and vomiting. Up to one-third of infected 
children may have a temperature higher than 39°C. The gastrointestinal symptoms 
generally resolve in three to seven days. The clinical features and stool characteristics of 
Rotavirus diarrhea are nonspecific, and other pathogens may cause similar illnesses. As a 
result, confirmation of a diarrheal illness as Rotavirus requires laboratory testing [31]. 
In one study, a comparison was made between (a) the clinical manifestations of 78 
patients hospitalized with Rotavirus diarrhea and (b) 72 patients hospitalized with a 
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diarrheal illness that was not associated with Rotavirus. The majority of both Rotavirus- 
and non–Rotavirus-infected children had a temperature of 37.9oC or above. Those with 
Rotavirus vomited and became dehydrated significantly more often than those who did not 
have Rotavirus. The mean duration of vomiting was longer in the Rotavirus-positive group 
than in those who did not have Rotavirus (2.6 days versus 0.9 days). Rotavirus diarrhea 
started later than vomiting but lasted longer (mean duration, five days versus 2.6 days). 
After infants and children were hospitalized, diarrhea continued for a mean of 2.6 days 
(range, 1 to 9 days) in the Rotavirus group and 3.8 days (range, 1 to 16 days) in the 
Rotavirus-negative group. The duration of hospitalization ranged from 2 to 14 days, with 
a mean of 4 days, for the patients infected with Rotavirus and for a mean of 6 days (range, 
2 to 27 days) for the Rotavirus-negative group [11]. 
2.4.2. Complications 
Rotavirus infection in infants and young children can lead to severe diarrhea, 
dehydration, electrolyte imbalance, and metabolic acidosis. Children who are 
immunocompromised because of congenital immunodeficiency or because of bone marrow 
or solid organ transplantation may experience severe or prolonged Rotavirus gastroenteritis 
and may have evidence of abnormalities in multiple organ systems, particularly the kidney 
and liver [31]. 
2.4.3. Diagnosis 
Rotavirus can be detected in stool specimens from children with gastroenteritis by 
several techniques, including electron microscopy, polyacrylamide gel electrophoresis, 
antigen detection assays, reverse transcription-polymerase chain reaction (PCR), and virus 
isolation [32]. 
Children with gastroenteritis are not routinely tested for Rotavirus because the 
results do not alter treatment. When testing is performed, antigen detection tests - including 
commercially available enzyme-linked immunosorbent assays (ELISAs) and 
immunochromatographic assays - are widely used. Most of these tests have high sensitivity 
and specificity (90-95%) [33]. The window for the detection of viral shedding using ELISA 
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usually ends within one week after the onset of illness, but the virus can be detected for 
more extended periods by more-sensitive assays, such as PCR [34], [35]. 
PCR is widely used in research laboratories to detect the viral genome, which is 
more sensitive and permits the genotyping of virus isolates [34], [36]. It provides data on 
the VP7 and VP4 genotypes that form the basis of binary classification (G and P type, 
respectively) of Rotavirus strains [32]. 
2.5. TREATMENT 
2.5.1. General information 
A mild case of Rotavirus disease, where the child is active, shows no signs of 
dehydration, has had between zero and two vomiting episodes within 12 hours, has had a 
few loose or low output watery stools per day and has no fever or a low-grade fever, 
requires only observation. Symptoms can last for 1–5 days, but if they last for >1 week, 
medical consultation should be sought.  Increasing and/or intense vomiting and repeated 
episodes of watery diarrhea (for example, >1 episode per hour, especially if abundant) are 
the main features that indicate the need for specific treatment. 
WHO-recommended treatment, such as zinc supplements, oral rehydration 
therapy, and treatment with intravenous fluids, when needed, can help rehydrate children 
until the intestine can repair and recover [37], [38]. 
2.5.2. Fluid and electrolyte management  
In low-income countries, particularly in hard-to-reach areas where children do not 
have timely access to such medical care, severe disease can result in rapid dehydration, 
leading to electrolyte imbalance, shock, and death. Nevertheless, many of the world’s most 
impoverished children do not have access to oral rehydration therapy, despite it being 
inexpensive and effective. Oral rehydration therapy coverage hovers around 40% in many 
of the places where the highest number of diarrhea deaths occur [39]. The goal of treatment 
is avoiding or rapidly treating severe dehydration and maintaining protein-calorie intake to 
prevent death or worsening malnutrition. In middle-income and high-income countries, 
reducing hospitalization and the duration of diarrhea are the main goals.  
 
 14 
2.5.3. Dietary management  
Dietary management is an essential factor in the care of children with acute 
diarrhea [40]. In patients with dehydration, food withdrawal is advised for only 4–6 hours 
after initiating rehydration therapy [38], [41]. 
Breastfeeding should be encouraged and is never contraindicated. The 
administration of repetitive, small portions of regular undiluted milk formulas is 
recommended for infants and children >6 months of age. 
The administration of lactose-free formulas might reduce the duration of treatment 
and the risk of treatment failure [40] and can be considered for selected children, such as 
those requiring hospitalization [38]. Importantly, the maintenance of adequate protein-
calorie intake during the diarrhea episode using home-available, age-appropriate foods 
should be encouraged, especially in low-income settings [40]. 
2.5.4. Probiotics  
Commonly used probiotics for the treatment of acute diarrhea are lactic acid-
producing bacteria, such as Lactobacillus rhamnosus, Lactobacillus plantarum, several 
strains of Bifidobacteria and Enterococcus faecium (the SF68 strain), and yeast, such as 
Saccharomyces boulardii [42]. 
Most meta-analyses suggest a modest benefit of probiotics in reducing the duration 
of diarrhea by approximately one day and up to two days for Rotavirus-induced diarrhea, 
although studies have been performed mostly in middle-income and high-income 
countries, and some studies did not report a clear benefit [43], [44]. 
In low-income regions, treatment with probiotics has a positive 
immunomodulatory effect (that is, an increased anti-Rotavirus IgG response in individuals 
who received treatment compared with individuals who received a placebo), improves 
intestinal function in children with Rotavirus infection and might decrease repeat episodes 
of Rotavirus diarrhea [45], [46]. However, probiotics are not included in the standard of 




2.5.5. Other drugs  
Antiviral therapy for Rotavirus infection has been studied but remains mostly in 
preclinical stages. One exception is nitazoxanide, a broad-spectrum antiviral drug that has 
been reported to reduce the duration of diarrhea and the duration of hospitalization of 
children with acute Rotavirus diarrhea [47], [48], [49]. One study in hospitalized children 
five months to seven years of age reported a significant reduction in the median time to the 
resolution of all Rotavirus-associated gastrointestinal symptoms from 75 hours in children 
who received placebo treatment to 31 hours in children who received a 3-day course of 
nitazoxanide treatment [48]. 
Other potential therapies for Rotavirus gastroenteritis include racecadotril and 
smectite.  However, treatment with racecadotril did not reduce the proportion of patients 
with diarrhea five days after treatment. Besides, one meta-analysis of seven clinical trials 
reported that racecadotril treatment is more effective than a placebo or no intervention at 
reducing the duration of illness and stool output in children with acute diarrhea [50].  
Combination trials evaluating the simultaneous use of several treatments are 
lacking [51]. Indeed, improvements in treatment strategies are needed, especially in regions 
where Rotavirus-associated deaths occur and where vaccines are underutilized [35]. 
2.6. MODE OF TRANSMISSION [31] 
2.6.1. Reservoir  
The reservoir of Rotavirus is the gastrointestinal tract and stool of infected humans. 
Although Rotavirus infection occurs in many nonhuman mammals, the transmission of 
animal Rotaviruses to humans is believed to be rare and probably does not lead to clinical 
illness. Although immunodeficient persons may shed Rotavirus for a prolonged period, an 
actual carrier state has not been described.  
2.6.2. Transmission  
Person-to-person contact or exposure to aerosolized respiratory droplets are the 




2.6.3. Communicability  
Rotavirus is highly communicable, as evidenced by the nearly universal infection 
of children by age five years in the pre-vaccine era. Infected persons shed large quantities 
of virus in their stool beginning two days before the onset of diarrhea and for up to 10 days 
after onset of symptoms. Rotavirus may be detected in the stool of immunodeficient 
persons for more than 30 days after infection. Spread within families, institutions, hospitals, 
and child care settings are common.  
2.7. ROTAVIRUS EPIDEMIOLOGY AND BURDEN OF DISEASE 
2.7.1. Burden of disease 
Rotavirus infects nearly every child by the age of 3–5 years and is the leading cause 
of severe, dehydrating diarrhea in children less than five years old worldwide. WHO 
estimated that in 2008, approximately 453,000 (420,000–494,000) Rotavirus 
gastroenteritis-associated child deaths occurred worldwide. These fatalities accounted for 
about 5% of all child deaths and a cause-specific mortality rate of 86 deaths per 100,000 
population aged <5 years [1]. Rotavirus has a case-fatality rate (CFR) of approximately 
2.5% among children in developing countries who present to health facilities. This CFR is 
higher in areas without proper access to health care [52]. 
In 2013, an estimated 215,000 deaths related to Rotavirus gastroenteritis occurred 
in children under five years old, in which 49% was accounted for four countries (Nigeria, 
Pakistan, India, and the Democratic Republic of the Congo) [2]. 
In a study reporting the results of the Global Rotavirus Surveillance Network 
(GRSN) from 2008 to 2016: 403,140 children younger than five years of age admitted to 
hospital with AGE from 349 sites in 82 countries, of whom 132,736 (32.9%) were 
Rotavirus-positive [53].  
In more than 100 studies conducted around the world among children younger than 
five years of age who were hospitalized for diarrhea, Rotavirus was the most common cause 
of diarrhea (detected in 20–60% of cases). Prospective studies of children observed from 
birth to two years of age suggest that the incidence of Rotavirus diarrhea varies directly 
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with the intensity of surveillance. These studies indicated that 77% to 83% of children will 
have an episode of Rotavirus diarrhea in their first 2 to 3 years of life and, depending 
somewhat on the locale, seek medical attention or treatment [12]. 
In low-income countries the median age at the primary Rotavirus infection ranges 
from 6 to 9 months (80% occur among infants <1 year old) whereas, in high-income 
countries, the first episode may occasionally be delayed until the age of 2–5 years, though 
the majority still occur in infancy (65% occur among infants <1 year old) [1]. 
Infants and children with Rotavirus-associated gastroenteritis exhibited some 
dehydration, vomiting, and watery diarrhea, which indicate the severity of Rotavirus 
infection, more frequently than those with non-Rotavirus gastroenteritis [54]. There were 
significantly high rates of infection among children younger than two years old, especially 
those between 6 and 11 months old. The lower prevalence in older children could be due 
to acquired immunity through previous exposures [55]. 
2.7.2. Seasonality 
In most low-income countries in Asia and Africa, Rotavirus epidemiology is 
characterized by one or more periods of relatively intense Rotavirus circulation against a 
background of year-round transmission, whereas in high-income countries with temperate 
climates a distinct winter seasonality is typically observed. This difference, as well as 
differences in health care availability and childhood co-morbidity, drive the marked 
inequality in Rotavirus disease burden between low- and high-income countries [1]. 
Most studies discovered that the distinct winter seasonality of Rotavirus 
hospitalizations in a temperate environment stands on the contrary to the year-round 
disease seen in tropical climates. It means that a child born in a temperate setting right after 
the Rotavirus season may have to wait many months before encountering the first possible 
natural infection in the following winter. On the contrary, a child born in a tropical climate 
may be exposed any day. Consequently, the average age at first infection is often younger 
in developing countries in tropical areas. In such tropical countries, the early episode of 
Rotavirus disease occurs most often during the first year of life, whereas frequently in 
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developed countries, the highest prevalence of first Rotavirus infections occurs in the 
second year of life. Therefore, an effective vaccine program in a developing country may 
require earlier and higher levels of coverage than in a developed country [12]. 
2.7.3. Genotype diversity 
With the advent of Rotavirus genotyping by PCR, detailed studies of the Rotavirus 
molecular epidemiology have become possible. Genotyping has an enormous value for 
assessing the evolution and epidemiological pathways of Rotavirus in humans, mammals, 
and birds [15].  
Currently, 36 G and 51 P genotypes have been approved by the Rotavirus 
Classification Working Group [20]. Despite the broad genomic and antigenic diversity of 
Rotavirus, globally, only a small number of Rotavirus types have prevailed in humans 
during the past three decades. Currently, 5 G-P combinations (G1P[8], G2P[4], G3P[8], 
G4P[8]) and G9P[8]) account for approximately 90% of all human Rotavirus infections in 
many parts of the world; type G1P[8] is the most prevalent combination. However, data 
from countries in Asia and Africa show greater strain diversity with several Rotavirus types 
circulating simultaneously [1], [15]. 
An example in Asia is in Indonesia, data from 2015-2018 indicated that the most 
common G-P combination was equine-like G3P[8] (70.8%), followed by equine-like 
G3P[6] (12.4%), human G1P[8] (8.8%), G3P[6] (1.5%), and G1P[6] (0.7%). The dynamic 
changes in Rotavirus genotypes from equine-like G3 to typical human G1/G3 in Indonesia 
can occur even in the country with low Rotavirus vaccine coverage rate [56]. 
For unexplained reasons, fecal specimens from children from developed countries 
are typically infected with a single strain of virus of one of the common serotypes found 
globally,  while in developing countries, the rate of mixed infections with two or more 
strains can be as high as 30%. These mixed infections, as well as single-virus infections in 





The prevalent types may vary from one season to the next, even within the same 
geographical area; these natural variations are essential to keep in mind when monitoring 
ecologic changes in Rotavirus strains following the implementation of Rotavirus 
vaccination. The type of Rotavirus does not usually correlate with the severity of the 
disease. There are currently no known laboratory markers for Rotavirus virulence [1]. 
2.8. GLOBAL ROTAVIRUS SURVEILLANCE NETWORK 
2.8.1. Objectives of the surveillance 
For all countries, the primary objectives for the Rotavirus surveillance are to:  
- Determine the epidemiology and burden of Rotavirus hospitalizations; 
- Document the spectrum of clinical presentations and outcomes of Rotavirus 
cases; 
- Determine the age and seasonal distribution of Rotavirus hospitalizations; 
- Identify the prevalent, circulating strains of Rotavirus.  
For countries that have yet to introduce the Rotavirus vaccine, an objective is to:  
- Generate information to facilitate and support the introduction of the Rotavirus 
vaccine.  
For countries that have introduced the Rotavirus vaccine, objectives are to:  
- Monitor impact of Rotavirus vaccination on disease and changes in epidemiology 
and circulating strains after Rotavirus vaccine implementation  
- Estimate vaccine effectiveness by using surveillance as a platform for special 
studies.  





2.8.2. Case definitions and final classification [57] 
2.8.2.1. Suspected case definition for case finding  
Acute (<14 days) watery diarrhea, defined as three or more loose or watery stools 
in 24 hours in a child <5 years of age who is admitted for treatment of diarrhea to a hospital 
ward or emergency unit at a participating surveillance facility. Children with bloody 
diarrhea and nosocomial infections are excluded.  
2.8.2.2. Confirmed case definition  
A suspect case in whose stool the presence of Rotavirus is demonstrated by using 
an enzyme immunoassay (EIA) or PCR-based methods.  
2.8.2.3. Special considerations  
If diarrhea surveillance is also intended to identify other enteric pathogens, then 
some components of the suspect and confirmed case definition might change. For example, 
bloody diarrhea might be included.  
2.8.3. Specimen collection  
The whole stool is the preferred specimen. Collect a minimum of 1 mL of stool for 
basic confirmatory testing; 2 mL or more may be needed for additional testing, such as 
genotyping. A stool specimen should be obtained within 48 hours of hospital admission to 
avoid the detection of nosocomially acquired infections. Avoid using rectal swabs or swabs 
placed in bacterial media, which are not optimal for Rotavirus detection or characterization.  
Stool specimens should be placed in sterile screw-top containers, properly labeled. 
Samples can be stored temporarily at 4–8°C for up to one month. Ice packs can be used to 
keep samples cool. Freeze-thaw cycles should be avoided where possible. If prolonged 
storage is necessary, store at -70°C, as evidence suggests that the ability to characterize 
Rotaviruses declines during storage for years at -20°C.  
If stool samples are also tested for bacterial or parasitic pathogens by conventional 
methods, the specimens should be transported to the lab within two hours of collection and 
placed on appropriate media. Specimens should then be stored in a freezer at -20°C or 
colder until testing is performed.  
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2.8.4. Laboratory testing  
2.8.4.1. Confirmation methods  
EIAs are most commonly used for Rotavirus detection in the stool. Several EIA 
kits (PremierTM Rotaclone®, ProSpecTTM, and RIDASCREEN®) are available. Follow 
the manufacturer’s procedures for each kit. The sensitivity of EIAs is 75–82%, with 100% 
specificity [58]. Thus, occasional false negatives are possible, particularly at lower viral 
loads, though the clinical significance of Rotavirus at concentrations below the threshold 
of EIA detection is unclear [59].  
2.8.4.2. Additional testing  
Confirmatory testing of EIA results may be done by testing for the presence of the 
VP6 gene using PCR or NP6 and NSP3 genes by real-time reverse transcription PCR (RT-
PCR). Rotavirus strain characterization is done by using RT-PCR to identify both G and P 
types. A subset of Rotavirus-positive stools obtained from routine surveillance should be 
chosen for strain characterization. It is recommended that a minimum of 50–60 randomly 
selected specimens per year be genotyped from each country. The randomly selected 
sample should be proportional to the age and seasonal distribution of cases. Only specimens 
> 3mL should be chosen to avoid running out of material. All non-typeable isolates should 
be sent to an appropriate reference laboratory for sequencing.  
2.8.4.3. Laboratory quality control and assessment 
A standard proficiency panel of Rotavirus-positive and -negative stool samples can 
be obtained from the global or regional Rotavirus laboratories. Labs should also arrange to 
send some Rotavirus-positive stool specimens to a regional laboratory for independent 
confirmation of results. External Quality Assessment and Quality Control of the laboratory 
should be completed annually.  
2.8.4.4. Laboratory networks  
Participation in a Rotavirus surveillance network is voluntary. The Global 
Rotavirus Laboratory Network has more than 100 participating laboratories throughout the 
world [60]. The network focuses on conducting high-quality diagnostic testing for 
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Rotavirus diarrhea and characterizing the most prevalent strain genotypes in different 
countries and regions. The network promotes standardization of data collection and 
laboratory quality and control through a global external quality assessment program 
coordinated by WHO. As of December 2017, the network includes 187 laboratories, 
including 108 sentinel hospital laboratories, 69 national and provincial laboratories, 9 
Regional Reference Laboratories, and one Global Reference Laboratory. 
 
 
Figure 2.5: WHO Member States that reported data to the Global Rotavirus 
Surveillance Network, 2018. 
2.9. ROTAVIRUS VACCINE 
2.9.1. General information 
WHO recommends Rotavirus vaccines should be included in all national 
immunization programs and considered a priority, particularly in countries with high 
Rotavirus gastroenteritis-associated fatality rates, such as in south and south-eastern Asia 
and sub-Saharan Africa. Rotavirus vaccine was introduced in 101 countries by 2018, 
including four in some parts of the country. Global coverage was estimated at 35% [7]. 
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Four Rotavirus vaccines are currently available on the global market, but most are 
very expensive - around US$45 per dose in the private market. This cost is prohibitive for 
most low- and middle-income countries. A key strategy for creating and maintaining a 
long-term, financially sustainable supply of Rotavirus vaccines is for additional 
manufacturers - especially those based in emerging countries - to develop Rotavirus 
vaccines and enter the marketplace.  
In Vietnam, locally state-owned vaccine manufacturer POLYVAC produced a 
licensed Rotavirus vaccine - Rotavin-M1 - that is available in the domestic private market, 
and more than one million doses have been administered to infants across Vietnam since 
2012. The price of this Vietnamese-made vaccine is one-third the cost of an imported 
vaccine, at just $20 per dose [8] (Table 2.3).  
2.9.2. Vaccine efficacy 
Published randomized clinical trials are not adequately powered to conclude 
whether or not efficacy wanes for either Rotarix or Rotateq. 
With Rotateq, one randomized clinical trial that enrolled subjects from 11 
countries, reported efficacy against severe disease estimated at 98% (95% CI: 88%–100%) 
during the first Rotavirus season and 88% (95% CI: 49%–99%) during the second season. 
An extension of this trial demonstrated a sustained reduction in the number of 
hospitalizations for Rotavirus disease also three years after vaccination [1]. 
Reports from randomized clinical trials were consistent with little decrease in the 
efficacy of Rotarix against severe Rotavirus disease during the second season of follow-
up, from 83% (95% CI: 67%–92%) to 79% (95% CI: 66%–87%) in Latin America and 
from 96% (95% CI: 90%–99%) to 86% (95% CI: 76%–92%) in Europe. A randomized 
clinical trial of Rotarix conducted in three high-income settings in Asia reported sustained 
efficacy against severe Rotavirus gastroenteritis of 100% (95% CI: 67.5%–100%) during 




Table 2.3. Three vaccines licensed for use in Vietnam. 
Vaccine name Rotarix Rotateq Rotavin-M1 
Manufacturer GlaxoSmithKline 
Belgium 




License Licensed 2004; WHO 
prequalification 
Jan 2007 (vial) 









Formulation Monovalent attenuated 








in the vaccine 





Yes, broad protection 
demonstrated 

















year (low- and 
midle-income 
countries) 
49–85% 51–64% IgA: 80.6% 
IgG: 72.8-85.3% 
Dosage At least 106 of live 
attenuated human 
G1P[8] particles per 
dose 
A minimum titer of 
approximately 2.0 to 
2.8 x 106 infectious 
units per reassortant 
At least 2x106 of 
live attenuated 
human G1P[8] 
particles per dose 
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Vaccine name Rotarix Rotateq Rotavin-M1 
and not greater than 
116 x 106 infectious 
units per aggregate 
dose 
Schedule 2-dose 
Given on the same 
schedule as DPT1 and 2 
vaccine doses 
3-dose 
Given on the same 
schedule as DPT1, 2 
and 3 vaccine doses 
2-dose 
Minimum at 6 
weeks, At least 30 
days apart 
 
Presentation 1. Liquid vaccine in 
oral, single-dose 
applicator 




3. Lyophilized vaccine, 
reconstituted with 
CaCO3 buffer, oral 
applicator 
Liquid vaccine in 
oral, squeezable tube 
1 dose liquid 
vaccine in glass 
vial 
Shelf life 36 months 24 months 24 months at -25 
to -15°C 
2 months from 




Yes No No 
Storage 
requirements 
2–8°C, not frozen and 
protected from light 
2–8°C, not frozen 
and protected from 
light 





No increased risk 
detected 
No increased risk 
detected 









Low-level risk in some 
countries, not in others 
Low-level risk in 










Sources: [31], [61], [62]. 
2.9.3. Vaccine impact 
Globally, Rotavirus prevalence among children younger than five years of age 
admitted with AGE to hospitals or emergency units decreased by nearly 40% in countries 
after the introduction of Rotavirus vaccines into their national immunization programs. In 
contrast, no such reduction was observed in regions where it was not introduced. 
Reductions by WHO regions ranged from 26.4% (15.0–37.8) in the Eastern Mediterranean 
Region to 55.2% (43.0–67.4) in the European Region and were sustained in nine countries 
(contributing up to 31 sites) for 6–10 years. [53].  
Many studies identified the age distribution of children with Rotavirus 
gastroenteritis shifted towards older children after the Rotavirus vaccine introduction. The 
study based on Global Rotavirus Surveillance Network from 2008-2016 indicated that in 
the pre-vaccine period, 17.8% of Rotavirus gastroenteritis cases occurred in the 0–5-month 
age group, 38.8% in the 6–11-month age group, 29.7% in the 12–23-month age group, and 
13.7% in the 24–59-month age group. In the post-vaccine period, the proportion of 
Rotavirus gastroenteritis cases occurring in the 0–5-month age group decreased to 12.9% 
and that for 6–11-month age group decreased to 31.9%, whereas the proportion increased 
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for both the 12–23-month age group (to 36.4%) and the 24–59-month age group (to 18.8%; 
p<0.0001). An example of this trend is in Rwanda, the cumulative age distribution of 
Rotavirus gastroenteritis cases showed a rightward shift, with 56% of Rotavirus 
gastroenteritis hospital admissions occurring among infants in the pre-vaccine period 
compared with 31% after Rotavirus vaccine introduction [63]. Similarly, in Bolivia, there 
was a decrease in the proportion of Rotavirus gastroenteritis cases occurring by 12 months 
of age, from 67% in the pre-vaccine period to 55% in the post-vaccine period [64]. All 
remain to be seen whether this shift in the proportion of Rotavirus gastroenteritis cases to 
older ages is a reflection of improved protection shortly after vaccination, whether this shift 
will diminish over time as all cohorts up to fivwfive years of age are vaccinated, or whether 
the absolute number of Rotavirus gastroenteritis cases will change. Additionally, there 
might be differential enrollment practices by age between pre-vaccine and post-vaccine 
countries that would affect this age distribution, which would need further study [53]. 
Introduction of Rotavirus vaccination may be closely associated with the strain 
selection of Rotavirus genotypes [65], [66]. Besides, in Australia, the equine-like Rotavirus 
strain was found to be more common in areas where the Rotarix vaccine was being 
administered. These findings raise the possibility that the Rotarix	 vaccine is associated with 
the emergence of the equine-like strains and that Rotavirus vaccines may induce selective 
pressure that favors specific genotypes [65]. The G2P[4] genotype that re-emerged after 
the Rotavirus vaccine introduction in certain areas [67]. In rare instances,  reassortment 
between RotaTeq vaccine component strains of genotypes P7[5]G1 and P1A[8]G6 have 
been observed to occur during human in vivo replication. This vaccine-derived reassortant 
has been demonstrated to be transmissible and is capable of causing symptomatic 
gastroenteritis. Typically in the post-licensure vaccine era, this reassortant has been 
detected among 1–3% of detected Rotavirus surveillance cases that have undergone 




2.10. VIETNAM SITUATION 
2.10.1. Epidemiology 
Diarrheal diseases remain one of the major killers of children under five years 
old in Viet Nam [68], with 7.0 percent of under-5 children reportedly having diarrhea two 
weeks prior to Vietnam Multiple Indicator Cluster Survey 2014 [69, 70]. Management of 
diarrheal diseases among children remained relatively ineffective; only 57.8% of children 
with diarrhea were treated for dehydration [69]. 
 
Figure 2.6. Causes of child death, 2012 [71] . 
Estimates from 2013 determined that Vietnam had a total of 2,083 diarrhea-related 
deaths, of which 49.9% were due to Rotavirus. Rotavirus accounted for 3.1% total death 
of children under five years old [2]. Vietnam also had one of the highest Rotavirus 
hospitalization figures in South East Asia [3]. 
In 1998, Vietnam initiated Rotavirus surveillance under the WHO's auspices. The 
national surveillance conducted in 4 hospitals located across the country. In the nearest 
study from this sentinel surveillance, Rotavirus was detected in 46.7% of 8,889 children 
under five years of age enrolled in the surveillance. Rotavirus was detected year-round, but 
most Rotavirus gastroenteritis cases (77.1%) occurred between December and May, 
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corresponding to the Rotavirus seasonality. It is also found that the peaks varied by region. 
Rotavirus positivities varied between the youngest and oldest age, but children 6–11 
months old (38.8%) and 12–23 months old (38.4%) counted for most cases. There were a 
significant higher times of diarrhea within 24 hours (8.3 times, 95%CI: 8.1–8.4 times) and 
higher proportion of severe dehydration (12.9%) in Rotavirus positive group than that in 
negative group (7.7 times, 95% CI: 7.6–7.9 times; and 9.7%, respectively). A downtrend 
of prevalence of G1P[8] was observed from 82% in 2013 to 15% in 2015. G2P[4] was 
found in 5% of samples in 2012, 9% in 2013, 36% in 2014, and 28% in 2015 [4]. 
Meanwhile, another study conducted the same period in five provincial hospitals 
(2012-2015) revealed the Rotavirus prevalence at 50.2% (678 Rota-positive/1,350 acute 
diarrhea cases). The common human G1P[8] (32.2%) and G2P[4] (13.0%) strains were 
most predominant, less predominant was G8P[8] strain (10.5%). The G8P[8] lineage was 
not detected in samples until 2014 than 2015 witnessed a rocket of this genotype from 5.2% 
in 2014 to 44.8% in 2015. Full genome sequencing and phylogenetic analysis of G8P[8] 
sequences reveal that this lineage represents a non-reassortant, monophyletic clade closely 
related to other G8P[8] strains isolated recently in Europe and Asia, and has experienced 
an unprecedented spread across Vietnam within a short period [72]. 
An economic evaluation of Rotavirus disease burden conducted in Vietnam in 
2003 by Fischer et al. estimated that the Rotavirus disease burden is equivalent to an 
economic burden of an estimated $3.1 million in direct medical costs, $685,000 in direct 
nonmedical costs, and $1.5 million in indirect costs [5].  In 2009, data were collected from 
hospitalized children under five years old with symptoms of AGE was estimated that the 
costs of patients with and without Rotavirus were $217 and $158, respectively [6].  
2.10.2. Rotavirus vaccination in Vietnam 
The study of Fischer et al. in 2003 found that universal Rotavirus vaccination in 
Viet Nam can prevent 70 percent of the outpatient visits, 84 percent of hospitalizations, 
and 83 percent of the related deaths [5]. Universal Rotavirus vaccination in Viet Nam can 
significantly reduce the burden of Rotavirus infections and diarrhea in children [71]. 
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However, to date, there is no available data about Rotavirus vaccine coverage in 
Vietnam. The country has been licensed two WHO-prequalified vaccines and one national-
licensed vaccine: 
Rotarix (GlaxoSmithKline, Rixensart, Belgium), which is based on the human 
Rotavirus G1P[8] strain, and RotaTeq (Merck and Company, Whitehouse Station, New 
Jersey, USA), consisting of 5 human-bovine recombinant strains.  
The Vietnamese local-state Rotavin-M1 vaccine, which is based on the G1P[8] 
strain, is similar to the monovalent Rotarix vaccine, but the viral strain of the Rotavin-M1 
vaccine is different from the Rotarix strain in both viral sequence and replication ability 
compared to the viral strain used in Rotarix. Rotavin-M1 has been available on the 
Vietnamese private market since 2012. 
However, Rotavin-M1 requires frozen storage at -20°C. It presents significant 
challenges for the vaccine cold chain in Vietnam, which was designed to keep vaccines at 
2-8°C. A second-generation formulation of their Rotavirus vaccine (called Rotavin) is 
evaluated, which does not need to be kept frozen, in a clinical trial in Vietnam. Rotavin 
contains the same Rotavirus strain as Rotavin-M1 and is produced in the same way, but 
only needs to be stored at 2-8°C. It is more compatible with the cold chain currently in 
place in Vietnam, allowing for more accessible storage and transport. It will also make the 
vaccine more attractive for use in many low- to middle- income settings, including in 
Vietnam. If the trial successfully confirms that Rotavin is as safe and immunogenic as the 
currently licensed frozen formulation, POLYVAC will apply for licensure of the new 
vaccine in Vietnam, and the government of Vietnam will consider its inclusion in the 
national immunization program. Besides, it may be possible in the future for POLYVAC 
to export Rotavin for use in other countries in the Mekong region.  
Improving access to Rotavirus vaccines in Vietnam will not only save children’s 
lives but also pave the way for a more sustainable and affordable Rotavirus vaccination 





MATERIALS AND METHODOLOGY 
 
3.1. STUDY DESIGN 
This study was a retrospective, hospital-based study conducted from 2013 to 2018 
at Children Hospital No.1 in Ho Chi Minh city, a site of the Vietnamese Rotavirus Sentinel 
Surveillance, in collaboration with the Pasteur Institute in Ho Chi Minh City. 
3.2. STUDY AREA 
3.2.1. Southern Vietnam 
Vietnam is a country in Southeast Asia, which has 93,67 million population, and 
the total fertility rate is 2.04 children born per woman (2017). In the north, the climate is 
monsoonal with four distinct seasons (Spring, Summer, Autumn, and Winter) while in the 
south (areas south of the Hải Vân Pass), the climate is tropical monsoon with two seasons 
(rainy and dry) [73]. 
The Vietnamese disease surveillance system divided into four administrative 
regions: Northern (28 provinces), Central (11 provinces), Highland (4 provinces), and 




Table 3.1. Southern Vietnam general informations 




Southeast (Đông Nam 
Bộ, Miền Đông) 
Ba Ria-Vung Tau, Binh Duong, 
Binh Phuoc, Dong Nai, Ho Chi 
Minh city, Tay Ninh, Lam Dong  
33,355.5 20,653,028 
Southwest (Tây Nam 
Bộ, Miền Tây) 
or Mekong River 
Delta (Đồng Bằng 
Sông Cửu Long) 
An Giang, Ben Tre, Bac Lieu, Ca 
Mau, Can Tho, Dong Thap, Hau 
Giang, Kien Giang, Long An, 





     









 3.2.2. Children’s Hospital No. 1 in Ho Chi Minh City 
Children’s Hospital No. 1 in Ho Chi Minh City is a major pediatric hospital serving 
children in Ho Chi Minh City and southern Vietnam. The 1,400-bed hospital provides the 
most specialized neonatal care in the South, assigned by the Ministry of Health to direct 
the route to the South West region and to implement the Satellite Hospital Project. The 
hospital is also a collaborative clinical pediatric clinic with leading hospitals and institutes 
throughout the country and the World Health Organization. 
The criteria to select this hospital were: 
- To represent of geographical character for the South of Vietnam; 
- To have the largest catchment population in the region; 
- To have a sufficient number of inpatients; 
- To have the capacity of human resources and logistics at hospitals. 
 
     






Figure 3.4. Flow diagram of Rotavirus sentinel surveillance in Southern Vietnam. 
Patients admitted to hospital 
Suspected case of Rotavirus: 
Acute watery diarrhea 
Specimen collection and 
storage (expected 700 
samples/ year) 
Fill in the Suspected 
Rotavirus reporting 
forms 
Collecting reporting forms and 
samples 
Laboratory: 
- ELISA test to identify       
Rotavirus positive, 
negative 
- PCR for genotyping 




- Data management and 
analysis 
- Reporting  






















3.3.1. Sampling method 
In Children Hospital No.1, the number of hospitalized acute diarrhea is high. So 
we could not include all the cases into the sentinel surveillance. The selection rule was:  
- For each case enrolled in the surveillance, hospital staff filled in the reporting 
form (Appendix 1) and collected the stool samples. 
- Expected enrolled cases for 15-20 cases per week, about 70 cases per month. 
- Selection method: Hospital staffs collected stool samples and reporting forms 
from the beginning of the week until the expected cases were reached. 
3.3.2. Included criteria 
For the sentinel surveillance, the definition of eligible children was children 
between 0 and 59 months of age whose primary reason for hospitalization was acute watery 
diarrhea, defined as ≥3 loose stools within 24 hours for <14 days between January 2013 
and December 2018. 
3.3.3. Exclusion criteria 
- Bloody diarrhea; 
- Diarrhea lasting ≥14 days before hospitalization; 
- Acquired acute watery diarrhea during hospitalization; 
- Parents/guardian does not allow their child to enroll in the surveillance. 
3.4. DATA COLLECTION 
Using a standard case definition and case-based data collection tool, hospital staffs 
prospectively identified children younger than five years of age admitted to the hospital or 
emergency unit with AGE to enroll in the surveillance. The informed consent was done by 
health workers, and the children were enrolled only when their parents or guardians agreed 
to participate in the surveillance. 
Enrolled children underwent a routine medical examination by a pediatrician, 
including the assessment of dehydration status and temperature. 
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Demographic data, medical history, and clinical presentation/characteristics, 
vaccination history, were collected by the interview with the subjects’ parents/guardians. 
Reviews of medical records collected information such as date of discharge, 
disease outcomes, and discharge diagnosis. All information was written into the 
standardized case investigation form. After consent, a stool specimen was obtained from 
each child enrolled within 48 hours after admission for laboratory confirmation of 
Rotavirus.  
3.5. SPECIMEN STORAGE AND LABORATORY TESTING 
Fecal specimens were collected and stored at 20oC after collection by Children 
Hospital No.1, then were shipped to Pasteur Institute in Ho Chi Minh city, which located 
approximately three kilometers from the Hospital. 
At Pasteur Institute in Ho Chi Minh city's Laboratory, specimens were tested for 
Rotavirus by a commercial ELISA ProSpecT (Oxoid; Basingstoke, UK).  At least 
twenty-five percent of ELISA positive samples randomly underwent P and G genotyping 
with a semi-nested multiplex reverse-transcriptase polymerase chain reaction using 
methods described in the WHO manual [57].   
3.6. STUDY VARIABLES 
3.6.1. Demographics characteristics 
- Age (in months): Divided into four groups (<6 months, 6-11 months, 12-23 
months, 24-59 months). 
- Gender (male/ female). 
- Time of admission: month, year. 
- Geographic information: 
+ Province; 
+ Geographic regions: South-eastern region (7 provinces: Ba Ria-Vung Tau, 
Binh Duong, Binh Phuoc, Dong Nai, Ho Chi Minh city, Tay Ninh, Lam 
Dong), South-western (13 provinces: An Giang, Ben Tre, Bac Lieu, Ca Mau, 
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Can Tho, Dong Thap, Hau Giang, Kien Giang, Long An, Soc Trang, Tien 
Giang, Tra Vinh, Vinh Long), and other regions (for children had address in 
other provinces). 
3.6.2. Clinical data  
- Presence of vomiting. If present:  
+ Maximum number of vomiting episodes in 24 hours at the peak of illness;  
+ Duration of vomiting in days. 
- Dehydration (none, mild-moderate, severe). 
- History of fever (Yes/No). Maximum body temperature. 
- A maximum number of diarrhea episodes in a 24-hour period, at the peak of 
illness. 
- Duration of diarrhea (days). 
- Treatment: oral rehydration solution (ORS), intravenous fluids (IV), antibiotics, 
probiotics, others (specify). 
- The case outcome at discharge (discharged alive, alive with sequelae, died, 
transferred, left/ discharged against medical advice, unknown). 
- Duration of hospitalization. 
- Mortality. 
3.6.3. Vaccination history  
- Rotavirus vaccination history before infection (yes/no). 
- Source of vaccination information (vaccination card, medical records, clinic 
logbook, maternal recall, other). 
- If yes: 
+ Type of Rotavirus vaccine (Rotarix, RotaTeq, Rotavin-M1, unknown); 
+ Number of doses received; 
+ Dates received; 
+ Status of immunization (Completed, Incompleted, Unknown). 
 
 39 
3.6.4. Specimen  
- Was the stool specimen collected from the case? 
- Stool specimen ID (to be provided if stool specimen ID differs from unique case 
ID). 
- Date of stool collection from the case. 
- ELISA test was done on stool specimen: 
+ Date of ELISA test on stool specimen; 
+ ELISA results for stool specimen (positive, negative, indeterminate).  
- PCR Genotyping done (on a subset of specimens): 
+ Date when genotyping was performed; 
+ Genotyping results (G-type); 
+ Genotyping results (P-type). 
3.7. ETHICAL CONSIDERATIONS 
The sentinel surveillance was approved by the Ministry of Health for the currently 
applicable regulatory requirements. Because this was a retrospective review of sentinel 
surveillance, new written informed consent from caregivers was not obtained. Patient 
names were not used; instead, unique identification codes were used in order to ensure 
confidentiality. 
3.8. DATA ANALYSIS 
Data gathered from sentinel hospitals were entered into an online software of 
Microsoft Office Access 2010 for six years from 2013 to 2018. We used Microsoft Office 
Excel 2010, SPSS 20.0 for our analyses. The map of Southern Vietnam was designed by 
ARCGIC. 
Children who did not meet with inclusion criteria or specimen failure will be 
excluded from the analysis. 
Regarding geographic regions, based on the divided of the Vietnamese disease 
surveillance system, we divided subjects into three groups: South-eastern region (7 
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provinces: Ba Ria-Vung Tau, Binh Duong, Binh Phuoc, Dong Nai, Ho Chi Minh city, Tay 
Ninh, Lam Dong), South-western (13 provinces: An Giang, Ben Tre, Bac Lieu, Ca Mau, 
Can Tho, Dong Thap, Hau Giang, Kien Giang, Long An, Soc Trang, Tien Giang, Tra Vinh, 
Vinh Long), and other regions (for children had address in other provinces). 
Regarding month of admission, to emphasize the seasonal trend, we divided into 
two groups: Dry season (November to April), and Rainy season (May to October). 
Categorical variables were compared using Chi-square tests, and continuous 
variables with normal distributions were compared using the ANOVA test. Records with 
missing values were excluded while running the statistical analysis for this variable. Mean 
and 95% confidence interval of continuous variables were estimated from the observed. 
Vesikari scale 
We assessed the severity of diarrheal symptoms by using the Vesikari Clinical 
Severity Scoring System. It  is currently recognized as the most accurate system for use in 
developing country vaccine trials [76]. It is a composite measure that relies on the clinical 
presentation profile of Rotavirus to identify severe Rotavirus gastroenteritis episodes, in 
which a higher score indicates increased disease severity. 
There are seven scoring parameters included in the Vesikari Clinical Severity 
Scoring System. These parameters take into account each of the symptoms identified as 
important in the clinical presentation profile: diarrhea, vomiting, fever, dehydration, and 
the duration of diarrhea and vomiting. An additional parameter considered is treatment 
status. The seven parameters and the corresponding scores provided for each categorical 
level of severity are outlined in Table 3.2. Severity scores above 10 points (i.e., ≥11 points) 
are considered severe, scores between 7 and 10 are moderate, and scores less than 7 are 




Table 3.2. Vesikari clinical severity scoring system parameters and scores. 
Parameter 1 2 3 
Diarrhea    
Maximum number stools per day 1-3 times 4-5 times ≥ 6 times 
Diarrhea duration (days) 1-4 days 5 days ≥ 6 days 
Vomitting    
Maximum number per day 1 2-4 times ≥ 5 times 
Vomitting duration (days) 1 2 ≥ 3 days 
Maximum body temperature 37.1-38.4 38.5-38.9 ≥ 39 
Dehydration N/A 1-5% ≥ 6% 
Treatment ORS Hospitalization N/A 
Table 3.3. Vesikari clinical severity scoring system severity rating scale. 
Level Mild Moderate Severe 
Score <7 7–10 ≥11 
 
Vaccine effectiveness: 
Children were included in the VE analysis if they were aged at least six months at 
the time of notification. This age cut off for the analysis was applied to avoid the inclusion 
of young infants notified as having Rotavirus disease but who had vaccine virus shedding. 
A dose was considered valid if the Rotavirus infection notification date was >14 days after 
receipt of the Rotavirus vaccine to allow for time to develop a protective immune response.  
We compared the VE against Rotavirus AGE of the completed vaccination group 
with the unvaccinated group. For genotype subgroup, we derived VE using the defined 
subgroup as cases and comparing Rotavirus-negative controls. 
The VE against Rotavirus AGE was calculated using the formula: 
VE = (1 − crude OR) × 100 (%). 







4.1. CHARACTERISTIC OF THE STUDY POPULATION 
Of 5,254 children with acute diarrhea extracted from the sentinel surveillance, 
5,179 cases were included in the study. Seventy-five cases were subsequently excluded 
because of some reason describing in the flow diagram. 2,424 ELISA positive Rotavirus 
stools were identified, accounted for 46.80% of the study sample. 
 
 
Figure 4.1. Flow diagram of enrollment of diarrhea cases in the sentinel 
surveillance, Southern Vietnam, 2013-2018. 
Hospitalized children (<5 years old) with acute diarrhea, 
N=5,254
Enrolled children with acute diarrhea, N=5,179 (98.57%)
Excluded, N=75
▪Missing data (age, gender, 
address, laboratory results): 61 
cases
▪Age > 5 years old: 13 cases
▪ Duplicate: 1
Positive for Rotavirus ELISA, N=2,424
(46.80%)
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N=5,179 N=2,424 N=2,758 
n (%) n (%) n (%) 
Age               
Average age 13.03±8.42 14.03±8.48 12.15±8.27 <0.001a*** 
< 6 months 572 11.04 178 7.34 394 14.30 
<0.001b*** 
6-11 months 2,169 41.88 940 38.78 1,229 44.61 
12-23 months 1,914 36.96 1,019 42.04 895 32.49 
24-59 months 524 10.12 287 11.84 237 8.60 
Gender              
Male 3,317 64.05 1,554 64.11 1,763 63.99 
0.93b 
Female 1,862 35.95 870 35.89 992 36.01 
Geographic 
distributions 
             
South-eastern 
region 
2,812 54.30 1,242 51.24 1,570 56.99 
<0.001b*** South-western 
region 
1,852 35.76 930 38.37 922 33.47 
Other region 515 9.94 252 10.40 263 9.55 
Years              
2013 825 15.93 456 18.81 369 13.39 
<0.001b*** 
2014 842 16.26 388 16.01 454 16.48 
2015 827 15.97 374 15.43 453 16.44 
2016 914 17.65 417 17.20 497 18.04 
2017 958 18.50 435 17.95 523 18.98 










N=5,179 N=2,424 N=2,758 
n (%) n (%) n (%) 
Month              
January 360 6.95 253 10.44 107 3.88 
<0.001b*** 
February 334 6.45 241 9.94 93 3.38 
March 441 8.52 272 11.22 169 6.13 
April 393 7.59 177 7.30 216 7.84 
May 474 9.15 187 7.71 287 10.42 
June 376 7.26 93 3.84 283 10.27 
July 362 6.99 121 4.99 241 8.75 
August 499 9.64 175 7.22 324 11.76 
September 403 7.78 161 6.64 242 8.78 
October 444 8.57 177 7.30 267 9.69 
November 601 11.60 287 11.84 314 11.40 
December 492 9.50 280 11.55 212 7.70 
a ANOVA; b Chi-square test 
* p<0.05; **p<0.01; ***p<0.001 
4.1.1. Age distribution 
As is presented in Table 4.1, the mean admission age of all hospitalized children 
in the study was 13.02±8.42 months. Rotavirus positive group was significantly older than 
the Rotavirus negative group (14.03±8.48 versus 12.15±8.27, p<0.001). 
Table 4.1 also shows well over three quarters (78.84%) of the study population 
were from 6 to 23 months old. There was a significantly different in the Rotavirus positive 
rate between four age groups; children older than 23 months of age had the highest 
proportion of Rotavirus gastroenteritis (54.77%), while group 0–5 months had the lowest 




Figure 4.2. Age distribution of children admitted with acute diarrhea, Rotavirus 
positive cases, and percent positive, 2013–2018. 
4.1.2. Gender distribution 
Of the 5,179 fecal samples, males accounted for a higher percentage of acute 
diarrhea than females (64.05% compared to 35.95%) and Rotavirus positive cases (61.11% 
versus 35.89%), but it was not statistically significant (p>0.05). 
  
Figure 4.3. Gender distribution total sample tested, Rotavirus positive cases, and 
percent positive, 2013–2018. 
4.1.3.  Geographic distribution 
There was significantly different in the prevalence of Rotavirus in different regions 
(p<0.001). Compared to other regions, the South-eastern region had the highest 
hospitalized diarrhea cases (2,812 cases, constituted 54.30%); however, it had the lowest 
positive Rotavirus rate among sample tested (44.17%). South-western region only 
























































Figure 4.4. Geographic distribution of total sample tested, Rotavirus positive cases, 
and percent positive, 2013–2018. 
4.1.4. Yearly distribution 
Among all study population, there was a significant difference in the prevalence of 
Rotavirus in different years (p<0.001). A downward trend was observed in the Rotavirus 
positive rate from 2013 (55.27%) to 2018 (43.54%) (Figure 4.5). 
 
 
Figure 4.5. Yearly distribution of total sample tested, Rotavirus positive cases, and 
percent positive, 2013-2018. 
4.1.5. Monthly distribution and seasonality 
In terms of cumulative monthly distribution, the Rotavirus positive rate ranged 
from a maximum of 71.26% in February to a minimum of 24.73% in June (Figure 4.6). 
Acute diarrhea and Rotavirus infection were detected year-round; however, it can 



























































(from November to April) witnessed a higher occurrence of Rotavirus positive cases 
(62.29%, 1,510/2,424 cases) compared to rainy season months (May to October, 37.71%, 
914/2,424 cases), and this difference was statistically significant (p<0.001). 
 
Figure 4.6. Cumulative monthly distribution Rotavirus positive and negative cases 
of acute diarrhea, 2013-2018. 
 
Figure 4.7. Monthly distribution of Rotavirus AGE positivity from 2013 to 2018. 
 
Figure 4.8. Distribution of vaccination history in terms of total sample tested, 
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4.1.6. Vaccination history 
The percentage of vaccinees among the study population was meager at 3.84%. 
The positive rate in the vaccinated group was 18.59%, whereas in the unvaccinated group 
was 47.94%, the difference was statistically significant (p<0.001) (Figure 4.8). 
The majority of vaccinees took the Rotarix (67.34%, 134/199), in which 17 cases 
were positive with Rotavirus. There was a significantly difference in the Rotavirus 
positivity of different vaccine names (p<0.05) (Table 4.2). 







n (%) n (%) n (%) 
Rota vaccination history before infection (n=5,179) 
Unvaccinated 4,967 95.91 2,381 98.23 2586 93.87 
<0.001b*** 
Completed 130 2.51 18 0.74 112 4.07 
Incompleted 40 0.77 11 0.45 29 1.05 
Unknown vaccine 
name or dose 
29 0.56 8 0.33 21 0.76 
Unknown vaccine 
history 
13 0.25 6 0.25 7 0.25 
Vaccine names (n=199) 
Rotarix 134 67.34 17 45.95 117 72.22 
0.012b* 
Rotateq 27 13.57 10 27.03 17 10.49 
Rotavin 10 5.03 2 5.41 8 4.94 
Unknown vaccine 
name or dose 
28 14.07 8 21.62 20 12.35 
a ANOVA; b Chi-square test 




4.1.7. Clinical features of participants according to Rotavirus results, 2013-2018 
4.1.7.1. Clinical features 
Of 5,007 participants that had vomiting data, 2.914 (58.20%) presented vomiting. 
Vomiting symptom was significantly more common in rota-positive than in rota-negative 
AGE (64.31% compared to 52.92%, p<0.001). The average maximum number of vomiting 
per day and duration of vomiting in rota-positive AGE patients were fractionally higher 
than in those who had negative results (p<0.001). 
Of 3,512 hospitalized children who had data on fever symptoms, 1,105 cases 
(31.46%) had a fever. 33.46% (530/1,580) of Rotavirus AGE presented fever, while its 
percentage was considerably lower in negative cases (29.76%) (p<0.05). The difference 
between the average max temperature of rota-positive AGE and negative-AGE was not 
statistically significant (p>0.05). 
Most patients did not present dehydration (95.00%). There was a significantly 
different in dehydration status between rota-positive and negative patients (p<0.05). 
The average max number of diarrhea per day evaluated in 5,136 participants was 
7.92±3.14 days. The average number in rota-positive cases was slightly higher than in rota-
negative cases (8.06±3.15 compared to 7.80±3.13 days); the difference was statistically 
significant (p<0.01). The duration of diarrhea of the rota-positive AGE was shorter than 
the rota-negative AGE, but it was not statistically different (3.06±2.27 days compared to 
3.13±2.36 days, p>0.05). 
In the Vesikari scale, 44.73% of the Rota-positive AGE was severe, while its 
prevalence in the negative group was 32.76%. There was significantly different in the 
clinical severity between rota-positive and negative patients (p<0.001). 
4.1.7.2. Treatments 
The majority of hospitalized children was treated with ORS; the different between 
rota-positive and negative group was not statistically significant (p>0.05). 
Of 438 children required IV treatment, children with Rotavirus-positive AGE were 
more likely to require IV than children with Rotavirus-negative AGE (p<0.01). 
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Of 441 children treated with antibiotics, children with rota-positive AGE were less 
likely to use antibiotics than the negative group;	the difference was statistically significant 
(p<0.01). 
Probiotic was given to nearly one-fourth of the patients; there was no statistical 
difference between the percentage of probiotic treatment in different Rotavirus results 
(p>0.05). 
The average of hospitalization days for all patients from 2013-2018 was 4.45±3.96 
days. The hospitalization duration of Rotavirus positive children was shorter than 
Rotavirus-negative AGE (4.25±3.69 versus 4.63±4.18 days). The difference was 
statistically significant (p<0.01). 
4.1.7.3. Mortality 
Of 5,083 cases who had data on the status of discharge, there was a Rotavirus 
associated death reported. The five-month-old child admitted to hospital in February of 
2017 and was dead after eight days of hospitalization. The duration of diarrhea was two 
days, maximum number of diarrhea was seven times per day. He had vomiting for three 
times in one day, and no dehydration symptom. He also presented a fever with the highest 
temperature was 38-degree Celsius. The case was not randomized chosen for PCR 











n % n % n % 
Clinical features 
Vomitting (n=5,007)        
   Yes 2,914 58.20 1,492 64.31 1,422 52.92 
<0.001b*** 
   None 2,093 41.80 828 35.69 1,265 47.08 
Average max. 
number of vomiting 
























(n = 5,120) 
       
none 4,864 95.00 2261 94.29 2,603 95.63 
0.011b* mild-moderate 239 4.67 132 5.50 107 3.93 
severe 17 0.33 5 0.21 12 0.44 
Fever (n = 3,512)        
  Yes 1,105 31.46 530 33.54 575 29.76 
0.016b* 









































n % n % n % 
Vesikari score 
(n = 3,356) 
       
< 7 (mild) 972 28.96 386 25.58 586 31.73 
<0.001b*** 7-10 (moderate) 1,104 32.90 448 29.69 656 35.52 
≥11 (severe) 1,280 38.14 675 44.73 605 32.76 
Treatment 
ORS (n = 5,159) 5,012 97.15 2,353 97.43 2,659 96.90 0.25a 
IV (n = 5159) 438 8.49 236 9.77 202 7.36 0.002 b** 
Antibiotics 
(n = 5,159) 
441 8.55 169 7.00 272 9.91 0.001b** 










2,659 4.63±4.19 <0.001a** 
Mortality (n=5,083) 1 0.02 1 0.02 0 0  
a ANOVA; b Chi-square test 
* p<0.05; **p<0.01; ***p<0.001 
There was some missing data according to each variables. 
4.2. CHARACTERISTICS OF PATIENTS WITH ROTAVIRUS 
GASTROENTERITIS ACCORDING TO VACCINATION STATUS 
Of 2,418 Rotavirus AGE children who had data on the history of vaccination, a 
small proportion was vaccinated (1.53%). There were no statistically significant in the 
prevalence of vaccine status in different groups of age, years, months, clinical features, and 
outcome (p<0.05). 
The different between vaccination status in different geographic regions and 
different gender groups was statistically significant (p<0.05). 
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Table 4.4. Characteristics of patients with Rotavirus gastroenteritis according to 
vaccination status, 2013-2018. 
Characteristics 
Total Vaccine group Non-vaccine group p-
value n % n % n % 
Age (n=2,418)        
Average 14.01±8.44 13.11±5.79 14.02±8.47 0.514a 
< 6 months 177 7.32 3 8.11 174 7.31 
0.17b 
6-11 months 939 38.83 12 32.43 927 38.93 
12-23 months 1,017 42.06 21 56.76 996 41.83 
24-59 months 285 11.79 1 2.7 284 11.93 
Gender 
(n = 2,418) 
       
Male 1,549 64.06 18 48.65 1,531 64.3 
0.049b* 
Female 869 35.98 19 51.35 850 35.7 
Years (n = 2,418)        
2013 456 18.88 12 32.43 444 18.65 
0.237b 
2014 386 15.98 7 18.92 379 15.92 
2015 373 15.45 6 16.22 367 15.41 
2016 416 17.23 5 13.51 411 17.26 
2017 434 17.97 5 13.51 429 18.02 
2018 353 14.62 2 5.41 351 14.74 
Month 
(n = 2,418) 
       
January 253 10.48 2 5.41 251 10.54 
0.603b 
February 241 9.98 4 10.81 237 9.95 
March 271 11.22 2 5.41 269 11.3 
April 176 7.29 5 13.51 171 7.18 
May 187 7.74 5 13.51 182 7.64 
June 91 3.77 2 5.41 89 3.74 




Total Vaccine group Non-vaccine group p-
value n % n % n % 
August 175 7.25 3 8.11 172 7.22 
September 161 6.67 0 0 161 6.76 
October 177 7.33 4 10.81 173 7.27 
November 287 11.88 4 10.81 283 11.89 
December 279 11.55 4 10.81 275 11.55 
Geography 
(n = 2,418) 
       
South-eastern 1,239 51.30 27 72.97 1,212 50.9 
0.028b* South-western 927 38.39 8 21.62 919 38.6 
Other region 252 10.43 2 5.41 250 10.5 
Clinical features (##) 
Average max. 
number of 
vomiting per day 
2,295 3.63±3.70 34 3.41±3.64 2,261 3.64±3.71 0.731a 
Duration of 
vomitting 
2,262 2.64±2.96 33 2.88±3.04 2,229 2.64±2.96 0.646a 
Vomitting  
(n = 2,316) 
      
0.959b 
   Yes 1,490 64.34 22 64.71 1,468 64.33 
   None 826 35.66 12 35.29 814 35.67 
Dehydration 
(n = 2,394) 
       
none 2,258 94.32 36 97.3 2,222 94.27 
0.725b mild-moderate 131 5.47 1 2.7 130 5.52 




Total Vaccine group Non-vaccine group p-
value n % n % n % 
Fever (n = 1,576)        
  Yes 527 33.44 7 38.89 520 33.38 
0.622b 
  No 1,049 66.56 11 61.11 1,038 66.62 
Average max 
temperature 
607 38.32±0.74 10 
37.89±0.7
8 
597 38.33±0.74 0.062a 
Average max. 
number of 
diarrhea per day 
2,401 8.06±3.15 37 8.51±3.72 2,364 8.05±3.14 0.384a 
Diarrhea duration  2,008 3.06±2.27 30 3.50±2.73 1,978 3.05±2.26 0.283a 
Vesikari score 
(n = 1,505) 
       
  < 7 (mild) 386 25.65 4 23.53 382 25.67 
0.876b   7-10 (moderate) 446 29.63 6 35.29 440 29.57 
  ≥11 (severe) 673 44.72 7 41.18 666 44.76 
Treatment  (##)        
ORS (n = 2,408) 2,349 97.55 36 100 2,313 97.39 0.326b 
IV (n= 2,408) 236 9.80 5 13.89 231 9.73 0.406b 
Antibiotics 
(n = 2,408) 
169 7.02 3 8.33 166 6.99 0.748b 
Probiotics 
(n = 1,580) 
358 22.66 2 11.11 356 22.79 0.239b 
Outcome (##)        
Duration of 
hopitalization 
2,327 4.24±3.69 34 4.85±5.42 2,293 4.24±3.65 0.335a 
Mortality 
(n=2,376) 
1 0.04 0 0 1 0.04  
a ANOVA; b Chi-square test 
* p<0.05; **p<0.01; ***p<0.001 
(##) There was some missing data. 
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4.3. GENOTYPE DISTRIBUTIONS  




P type Total 



















G1 12 3 143 0 0 0 0 1 0 0 159 14.36 
G2 142 0 20 0 0 0 0 2 0 0 164 14.81 
G3 9 2 478 5 1 0 2 0 0 0 497 44.90 
G4 0 3 2 0 0 0 0 0 0 0 5 0.45 
G5 0 0 0 0 0 1 0 0 0 0 1 0.09 
G8 1 1 218 0 0 0 0 1 0 1 222 20.05 
G9 1 2 38 0 0 0 1 1 0 0 43 3.88 
GNt 0 0 3 0 0 0 0 0 0 0 3 0.27 
G1/ 
G3 
2 0 9 0 0 0 0 0 1 0 12 1.08 
G3/ 
G4 
0 0 1 0 0 0 0 0 0 0 1 0.09 
Total 167 11 912 5 1 1 3 5 1 1 1107 100 
Total 
(%) 





Figure 4.9. Genotypes distribution from Rotavirus positive cases isolated by PCR in 
sentinel surveillance, 2013-2018. 
 
Figure 4.10. Positive rate among all AGE and genotype distribution according to 


















Overall, of 1,107 Rotavirus positive cases had PCR isolated for genotyping. 
G3 was the predominant G genotype, accounted for 44.90% (497/1,107). P[8] was 
the most frequently P genotype, constituted 82.38% (912/1,1107) (Table 4.5). 
G3P[8] was the most common G-P combined genotype (43.18%), followed by 
G8P[8], G1P[8], G2P[4] (constituted 19.69%, 12.92%, and 12.83%, respectively). 
Regarding G-P genotype combination according to year distribution, we observed  
an enormous shift from 2013 to 2018 (Figure 4.9): 
- There was a considerable decline of G1P[8] from 69.92% in 2013 to no cases in 
2018. 
- G3P[8] became more frequent during 2014-2018, with the rise from 8.13% in 
2013 to a peak of 60.65% in 2017, then decreased to 41.15% in 2018. 
- There also occurred a change in G8P[8] and G2P[4] prevalence. From no case in 
2013, G8P[8] leaped to a peak of 47.21% in 2016 and was the predominant 
genotype at that year, before went down to 23.92% in 2018. 
- G2P[4] showed a slight upward trend from 2013 to 2014 (from 15.45% to 
37.41%), then dropped to 0.43% in 2016, before went up to 16.27% in 2018. 
In terms of geographic distribution, G3P[8] was the highest prevalence in most 
provinces, except Can Tho. In Can Tho, 27.27% genotypes isolated was G8P[8], equal with 




4.4. RISK ANALYSIS FOR ROTAVIRUS GASTROENTERITIS AMONG 
CHILDREN UNDER FIVE YEARS OF AGE 
Table 4.6. Risk analysis for Rotavirus AGE, 2013-2018 (n=5,166). 
Variables 
Crude Adjusted 
OR 95%CI p OR 95%CI p 
Age         
< 6 months Ref. - - - Ref. - - - 
6-11 months 1.693 1.391 2.06 <0.001 1.678 1.369 2.058 <0.001*** 
12-23 months 2.52 2.066 3.073 <0.001 2.543 2.069 3.126 <0.001*** 
24-59 months 2.68 2.094 3.431 <0.001 2.568 1.988 3.317 <0.001*** 
Sex         
Male Ref. - - - Ref. - - - 
Female 0.995 0.888 1.115 0.931 0.993 0.882 1.119 0.914 
Visit year         
2013 Ref. - - - Ref. - - - 
2014 0.692 0.57 0.839 <0.001 0.655 0.535 0.801 <0.001*** 
2015 0.668 0.55 0.811 <0.001 0.659 0.538 0.807 <0.001*** 
2016 0.679 0.562 0.82 <0.001 0.655 0.537 0.798 <0.001*** 
2017 0.673 0.558 0.812 <0.001 0.588 0.483 0.716 <0.001*** 
2018 0.624 0.513 0.759 <0.001 0.549 0.447 0.674 <0.001*** 
Month         
Rainy season  Ref. - - - Ref. - - - 
Dry season 2.445 2.186 2.734 <0.001 2.4 2.14 2.692 <0.001*** 
Geographic 
distributions         
South-eastern Ref. - - - Ref. - - - 
South-western 1.275 1.134 1.434 <0.001 1.285 1.135 1.455 <0.001*** 
Others 1.211 1.004 1.462 0.046 1.249 1.025 1.522 0.028* 
Rotavirus 
vaccination         
Unvaccinated Ref. - - - Ref. - - - 
Vaccinated (at 
lease one dose) 0.248 0.173 0.356 <0.001 0.273 0.188 0.396 <0.001
*** 
* p<0.05; **p<0.01; ***p<0.001 
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 It was discovered that Rotavirus AGE was more likely to be found in children 
older than six months; compared to the under six months group: 
- The odds of Rotavirus AGE in the 6-11 months group was 1.68 times higher  
(OR=1.678, 95%CI: 1.369 - 2.058, p<0.001). 
- The odds of Rotavirus AGE in the 12-23 months group was 2.54 times higher 
(OR=2.543, 95% CI: 2.069 - 3.126, p<0.001) 
- The odds of Rotavirus AGE in the 24-59 months group was 2.57 times higher 
(OR=2.568, 95% CI: 1.988 - 3.317, p<0.001). 
Compared to the South-eastern region, Rotavirus AGE was more likely to occur in 
the South-western (OR=1.285, 95% CI: 1.135 - 1.455, p<0.001) and other region 
(OR=1.249, 95% CI: 1.025 - 1.522, p<0.05). 
Dry season months (from November to April) witnessed a 2.4 times higher 
occurrence of  Rotavirus positive cases compared to rainy season months (May to October) 
(OR=2.4, 95% CI: 2.14 - 2.692, p<0.001). 
Compared to the unvaccinated group, the vaccinated group (with at least one dose) 
was at lower risk for Rotavirus positive (OR=0.273, 95% CI: 0.188 - 0.396, p<0.001). 
4.5. VACCINE EFFECTIVENESS 
Among children ≥ 6 months of age who were age-eligible to have received a full 
schedule of the Rotavirus vaccine, getting a completed schedule of Rotavirus vaccine had 
vaccine effectiveness against Rotavirus AGE at 82.34% (95% CI: 70.33%-89.49%) (Table 
4.7). 
Considering Rotarix vaccine effectiveness, getting a completed schedule of Rotarix 
had vaccine effectiveness against Rotavirus AGE at 85.90% (95% CI: 74.10%-92.30%). 








schedule Unvaccinated VE 
95%CI 
p 
cases control cases control - - 
All vaccine         
VE 17 97 2,207 2,224 82.34 70.33 89.49 <0.001*** 
G1P[8] 1 97 131 2,224 82.50 -26.50 97.58 0.08 
G2P[4] 2 97 133 2,224 65.52 -41.36 91.59 0.14 
G3P[8] 2 97 444 2,224 89.67 57.96 97.46 0.002** 
G8P[8] 2 97 202 2,224 77.30 7.25 94.44 0.039* 
Rotarix only         
VE 12 86 2,207 2,224 85.90 74.10 92.30 <0.001*** 
G1P[8] 0 86 131 2,224 100 - 100 0.08 
G2P[4] 2 86 133 2,224 61.11 -59.73 90.53 0.19 
G3P[8] 2 86 444 2,224 88.35 52.50 97.14 0.003** 
G8P[8] 2 86 202 2,224 74.40 -4.80 93.74 0.06 








This retrospective study presented a 7-year result of the Rotavirus sentinel 
surveillance in Southern Vietnam from 2013 to 2018.  
Several Rotavirus-associated diarrhea research had been performed across the 
country [4, 6, 62, 68, 72, 77-92]; however, most studies only focus on epidemiological and 
genotyping features. Our study not only provided an updated picture of Rotavirus 
epidemiology and genotypes but also discovered the clinical features and vaccination status 
among study population when the Rotavirus vaccine is self-financed in Vietnam. 
5.1. CHARACTERISTIC OF STUDY POPULATION ACCORDING TO 
ROTAVIRUS ELISA RESULTS, 2013-2018 
Of 5,179 acute diarrhea cases included in the study, Rotavirus was detected in 
2,424 cases (46.80%). This prevalence was in harmony with the previous results in 
Vietnam during 2012-2015: the National Sentinel Surveillance report (46.66%, 
4,054/8,689 cases) [4], as well as a study in five provincial hospitals across the country 
(50.2%, 678/1,350 cases) [72]. Our result was considerably more elevated than the global 
median positive proportion in 2013 (37.3%) and lower than the Rotavirus detection rates 
of Southeast Asia (50.7%–54.6%) [2]. 
Compare to other recent study with the same methods, our positive rate was higher 
than in other ASEAN countries, such as: Philippines (34%, 2014-2017) [93], Indonesia 
(31.7%, 2015-2018) [56]; and other Asian countries, such as: China (20.8%, 2011-2016) 
[94], Korea (32.9%, 2012-2013) [95], India (45%, 2014-2016) [96]. It was slightly lower 
than in Cambodia (50%, 2010-2016) [97], and Myanmar (49.90%, 2009-2014) [98]. The 
high Rotavirus positivity in Vietnam could be because of the weather characteristic, level 
of socio-economic population, and other reasons that will be discussed afterward. 
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5.1.1. Age distribution 
The mean age of rota-positive AGE in this study was higher than the National 
Sentinel Surveillance data during 2012-2015 (13.7 months, 95% CI: 13.4–14.0) [4]. Our 
result was higher than the study in India (13.32 ± 9.55 months, between July 2014 and June 
2016) [96], and less than in Korea (19.8 ± 13.6 months, during 2012-2013) [95].  
We observed that Rotavirus diarrhea was more likely to be found in children older 
than six months. Using the under six months old group as reference variable, the odds of 
Rotavirus positive in other groups were higher. A lower positivity rate among children less 
than six months of age is probable that most of them are less contact to the outside world, 
and considered to be partially protected from Rotavirus infections by maternal antibodies 
through the placenta [99]. However, passive antibody titers wane over time and no longer 
confer protection after six months, which may explain why most children were infected 
with Rotavirus between 6 and 23 months [99]. A low positivity of Rotavirus was found 
among children from 24 months old could also be explained by the natural immunity 
conferred by past exposures [55]. Children can be infected Rotavirus more than one time, 
with the first episode of Rotavirus AGE by the first year of life. Several cohort studies 
described that one event of Rotavirus infection had a protective efficacy, and recurrent 
episodes of Rotavirus disease were less severe than the first episode [1], [4]. 
The similarity occurred in other countries. In China, the Rotavirus-positive rate 
was most common among the 1–2 years old age group [94]. Molecular epidemiological 
analysis in Indonesia described that Rotavirus infection was significantly more prevalent 
in the 6- to 11-month age group than in the other age groups (p<0.05) [56].  
Besides, the age shift also can happen after the Rotavirus vaccine introduction. A 
previous study based on Global Rotavirus Surveillance Network from 2008-2016 indicated 
that in the post-vaccine period, the proportion of Rotavirus gastroenteritis cases occurring 
in the 0–5-month age group and 6–11-month age group were dropped. In contrast, the 
incidence increased for both the 12–23-month and the 24–59-month age group. This trend 
also was discovered in Rwanda, the cumulative age distribution of Rotavirus AGE showed 
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a rightward shift, with 56% of Rotavirus gastroenteritis hospital admissions occurring 
among infants in the pre-vaccine period compared with 31% after Rotavirus vaccine 
introduction [63]. In a similar trend, there was a fall in the prevalence of Rotavirus cases 
occurring by 12 months of age in Bolivia, from 67% in the pre-vaccine period to 55% in 
the post-vaccine period [64]. It remains to be seen whether this shift in the proportion of 
Rotavirus AGE to older ages is a reflection of improved protection shortly after 
vaccination, or this shift will diminish over time as all cohorts up to five years of age are 
vaccinated, or the absolute number of Rotavirus gastroenteritis cases will change. Also, 
there might be differential enrollment practices by age between pre-vaccine and post-
vaccine countries that would affect this age distribution; this would need further study [53]. 
5.1.2. Gender distribution 
In our study, males accounted for a high percentage than females, but there was no 
statistically significant (p>0.05). A similar trend was observed in the study of Huyen et al. 
(64.6% male compared to 35.4% female) and the study of Chung et al. in Korea (the sex 
ratio of male: female was 1.23) [95].  
5.1.3.  Geographic distribution 
The South-eastern region had the highest hospitalized diarrhea cases (54.30%); 
however, compared to South-eastern region, Rotavirus AGE was more likely to occur in 
South-western and other region. 
This results may happen because the Children Hospital No. 1 in Ho Chi Minh city 
is located in the South-eastern region, so parents tended to take their child to the hospital 
if they appeared any symptoms. The South-western region is far from the hospital site, so 
parents tended to use the provincial hospitals or clinic services; only severe cases would be 
transferred or visit the Children Hospital No. 1. 
5.1.4. Yearly distribution 
A downward trend was observed in the Rotavirus positive rate from 2013 (55.27%) 
to 2018 (43.54%). A reduction also identified in the previous study in Vietnam [4]. There 
is a need to study further to identified the reason for this slip. 
 
 65 
5.1.5. Monthly distribution and seasonality  
The tropical climate in Southern Vietnam is characterized by high temperatures 
year-round and sunny weather. Mean annual temperatures in coastal areas are around 27°C 
that is fairly even throughout the year with little difference between the coldest and hottest 
months of the year. There are two seasons per year: rainy seasons from May to October, 
dry season from November to April. 
In our study, acute diarrhea and Rotavirus infection were detected throughout the 
year; however, it can be seen that Rotavirus positivity varied seasonally. Dry season months 
(from November to April) witnessed a higher occurrence of Rotavirus positive cases 
compared to rainy season months (May to October) (p<0.001). 
A similar trend was observed in other Southeast Asia countries, such as Thailand 
(the highest rate months each year were November, December, and January), and 
Cambodia (incidence peaks typically occurred between November-May) [94], [97]. By 
contrast, in Korea, a country is located in the temperate zone, Rotavirus detection peaked 
in March and April but rapidly decreased in May [95]. 
These results suggest that considerable attention to local climatic conditions may 
help our understanding of the prevalence of Rotavirus infection. Most studies discovered 
that the distinct winter seasonality of Rotavirus hospitalizations in temperate environment 
stands on the contrary to the year-round disease seen in tropical climates. It means that a 
child born in a temperate setting right after the Rotavirus season may have to wait many 
months before encountering the first possible natural infection in the following year’s 
winter. On the contrary, a child born in a tropical climate may be exposed any day. 
Consequently, the average age at first infection is often younger in developing countries in 
tropical areas. In such tropical countries, the early episode of Rotavirus disease occurs most 
often during the first year of life, whereas frequently in developed countries, the highest 
prevalence of first Rotavirus infections occurs in the second year of life. Therefore, an 
effective vaccine program in a developing country may require earlier and higher levels of 
coverage than in a developed country [12]. 
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5.1.6. Vaccination history 
Vietnam did not set surveillance on private sector vaccine, so to date, there is no 
available data about Rotavirus coverage in the country. In this study, the percentage of 
vaccinees among hospitalized AGE children was extremely low (3.84%). 
The Rotavirus vaccine in Vietnam is self-financed by caregivers. To get the vaccine 
in the private sector, the family should pay by themselves with a high price compared to 
Vietnamese income. That factor might be a reason for the low coverage of the Rotavirus 
vaccine in the country. Besides, other factors that should be considered are children whose 
mothers had relatively less household wealth, were from ethnic minorities, lived in rural 
areas, and had less education. At the community level, the child's region of residence was 
the main predictor of timely immunization completion, and the availability of hospital 
delivery and community prenatal care in the local community were also determinants [100]. 
Compared to the unvaccinated group, the vaccinated group was at lower risk for 
Rotavirus positive. A similar observation was described in Korea: the Rotavirus AGE 
incidence is lower in the Rotavirus-vaccinated group compared to the unvaccinated group 
with no evidence of substitution with unusual genotype combinations [95].  
5.1.7. Clinical features of participants according to Rotavirus results, 2013-2018 
5.1.7.1. Treatments 
According to WHO, no specific therapy is currently available against Rotaviruses. 
As with other childhood diarrheas, the corner-stones of treatment are fluid replacement to 
prevent dehydration, and zinc treatment, which decreases the severity and duration of 
diarrhea. Additional treatment measures during the diarrheal episode include continued 
feeding, including breast-feeding, and if ORS is not available, use of appropriate fluids 
available in the home [1]. 
In this study, children with rota-positive AGE were less likely to use antibiotics 
than the negative group;	the difference was statistically significant (p<0.01). The reason 
for this trend may because at the hospital, if the disease pathogen was not classified 




The hospitalization duration of Rotavirus positive children was shorter than 
Rotavirus-negative AGE (4.25±3.69 versus 4.63±4.18 days, p<0.001). The longer duration 
of hospitalization in Rotavirus negative group might happen because at the hospital, 
patients without an apparent disease pathogen tended to take a longer time to diagnosis and 
treatment. However, there still need more study to give evidence on the assumption. 
Mortality: There was one Rotavirus associated death reported. The mortality in 
this study is extremely low compared to the global CFR of approximately 2.5% among 
children in developing countries who present to health facilities. The CFR is higher in areas 
without proper access to health care [52]. The death case in our study was not randomized 
chosen for PCR genotyping, so we couldn't specify the genotype information for further 
analysis, this issue revealed a need of considering to include specific important cases into 
the PCR for genotyping in the process of sentinel surveillance. 
5.2. THE GENOTYPIC DIVERSITY OF ROTAVIRUS STRAINS DETECTED IN 
CHILDREN AGED <5 YEARS IN SOUTHERN VIETNAM, 2013-2018 
Genotyping has an enormous value for assessing the evolution and epidemiological 
pathways of Rotavirus in humans, mammals, and birds [15]. Despite the broad genomic 
and antigenic diversity of Rotavirus, globally, only a small number of Rotavirus types have 
prevailed in humans during the past three decades. Currently, 5 G-P combinations (G1P[8], 
G2P[4], G3P[8], G4P[8]) and G9P[8]) account for approximately 90% of all human 
Rotavirus infections in many parts of the world; type G1P[8] is the most prevalent 
combination. However, data from countries in Asia and Africa show greater strain diversity 
with several Rotavirus types circulating simultaneously; other genotypes such as G5, G6, 
and G8 are more prevalent [1], [15]. 
In our study, of 1,107 Rotavirus positive cases had PCR isolated for genotyping; 
G3 was the predominant G genotype, P[8] was the most frequently P genotype. G3P[8] 




We observed  an enormous shift from 2013 to 2018: G3P[8] became predominant 
while G1P[8] considerably dropped. Globally, after the vaccine introduction, the 
prevalence of G1P[8] strains has significantly decreased [65], [101]. In recent years, 
G3P[8] Rotavirus has emerged as a predominant genotype in several countries with a wide 
range of vaccine coverage, including Asia (Pakistan, Indonesia, Japan, Thailand), South-
America (Argentina), and Europe (Germany, Spain), Australia [56], [65], [102], [103]. The 
global emergence of G3P[8] strain happened irrespective of vaccine coverage, suggested 
that vaccines may not be highly effective against this strain. 
We also discovered a change in G8P[8] and G2P[4] prevalence. G8P[8] also 
emerged after 2014 in Thailand and caused outbreaks in Central Japan in 2014 and 2017 
[66]. G2P[4] strains had increased in circulation in many countries after the Rotarix vaccine 
introduction, such as Australia, Brazil, Belgium, and China [65], [104, 105]. This 
variability raised the question of whether the genotype changes were due to natural 
fluctuation of Rotavirus populations, or if the vaccines were less effective at protecting 
against certain strains. 
 It is difficult to determine the apparent cause of these genotyping changes. 
However, it is considered that Rotavirus diversity is generated by genetic drift, genetic 
shift, and zoonotic transmission [106]. Theoretically, any of the known P and G complexes 
could recombine to form new viruses, assuming these recombinations created sustainable 
viruses. Vaccine-induced immune pressure may be an additional selective pressure that 
leads to the evolution of Rotavirus strains capable of causing severe disease in vaccinated 
children [65]. Monitoring such changes is necessary to ensure the long-term safety of the 
Rotavirus vaccine. 
5.3. VACCINE EFFECTIVENESS 
Vietnam has licensed two WHO-prequalified vaccines and one national-licensed 
vaccine: Rotarix (GlaxoSmithKline, Rixensart, Belgium), which is based on the human 
Rotavirus G1P[8] strain; and RotaTeq (Merck and Company, Whitehouse Station, New 
Jersey, USA), consisting of five human-bovine recombinant strains. The Vietnamese local-
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state Rotavin-M1 vaccine, which is based on the G1P[8] strain, is similar to the monovalent 
Rotarix vaccine, but the viral sequence and replication ability of the Rotavin-M1 vaccine 
isis different from the Rotarix strain [8]. Introduction of Rotavirus vaccination may be 
closely associated with the strain selection of Rotavirus genotypes [65] [66]. The study of 
Fischer et al. in 2003 found that universal Rotavirus vaccination in Viet Nam can prevent 
70%  of the outpatient visits, 84% of hospitalizations, and 83% of the related deaths [5].  
Our study was conducted in the context of meager vaccine coverage. Among 
children ≥ 6 months of age who were age-eligible to have received a full schedule of 
Rotavirus vaccine, a 82.84% reduction against Rotavirus AGE was among children who 
got a full schedule of Rotavirus vaccine. Most of the vaccinated cases were used the Rotarix 
vaccine, so we did further analysis on the Rotarix VE. The VE of the completed Rotarix 
schedule (85.90%) was higher than overall VE. 
Our VE result is considered to be a high VE compare to other studies. A systematic 
review of 48 articles from 2006-2016 with post-licensure data from 24 countries showed a 
median Rotarix VE of 84%, 75%, and 57% in countries with low, medium, and high child 
mortality, respectively, and Rotateq VE of 90% and 45% in countries with low and high 
child mortality, respectively [107]. By income, vaccine effectiveness was high in high-
income countries with protection rates against severe Rotavirus disease at 80–90% [108], 
[109], [107]; it was 30–50% lower in low- and middle-income countries, mainly in sub-
Saharan Africa and South East Asia  [2], [110], [111], [112], [113], [107]. Several health 
conditions have been recognized as being important for the outcome of Rotavirus vaccine: 
malnutrition with deficiencies in micronutrients (zinc, vitamin A, vitamin D), connected 
with functional reduction of innate and acquired immune responses, and the gut 
microbiome which is of proven influence for disease severity and vaccine uptake. Maternal 
Rotavirus-specific antibodies are of variable importance for disease and vaccine outcomes. 
Specific diarrhea prevention programs (supply of nutrients and micronutrients, such as 




Besides, Moon et al. hypothesized that the neutralizing effect of breast milk could 
play an essential role in reducing the antigen dose when breast milk is consumed 
immediately before vaccination [114]. However, several newer studies have not shown any 
beneficial effect of temporarily withholding breastfeeding for 30 to 60 minutes before and 
after vaccine administration on the immune response to the Rotavirus vaccine [115], [116]. 
In 2010, there was a study conducted in Vietnam examined possible differences in breast 
milk Rotavirus-specific antibody level, focusing on the level of neutralizing activity against 
the Rotavin-M1 vaccine strain. An increase in neutralizing anti-G1P[8] antibody titers (P 
<0.05) in rural infants over time suggests a continuous exposure to circulating Rotavirus; 
breastfeeding could be hold off at the time of vaccination and resume one hour after vaccine 
delivery to enhance the immune responses in children [86].  
To introduce a Rotavirus vaccine in Vietnam, the strain diversity will be a 
challenge; G1P[8] used to be common but was declined, while G3P[8] Rotavirus has 
emerged as a predominant genotype. In this study, because the number of cases in G1P[8] 
was low, so we could not calculate the Rotarix VE this genotype; however, we identified a 
noticeable result that Rotarix VE for G3P[8] was high at 88.35% (95%CI: 52.50%-
97.14%). This result may reveal the cross-serotype protection provided by the Rotarix 
vaccine in Southern Vietnam, which will be a considerable reason while consider to use 
the Rotavirus monovalent vaccine in the country. 
The ability of Rotavirus monovalent vaccine to generate broader heterotypic 
protection was estimated in a systematic review in 2014: Rotavirus monovalent vaccine 
provided broad clinical efficacy and field effectiveness against severe diarrhea due to all 
major circulating strains, including the homotypic G1P[8], partially heterotypic (G3P[8], 
G4P[8], and G9P[8]), and fully heterotypic G2P[4] Rotavirus strains throughout different 
geographical and income settings. The pooled effectiveness of monovalent Rotavirus 
vaccine in these high and middle-income countries was 77% (95% CI: 58%-86%) against 
homotypic strains, 72% (95% CI: 49%-84%) against partially heterotypic strains, and 67% 
(95% CI: 52%-77%) against fully heterotypic strains [117]. 
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The cross-serotype protection mechanisms of Rotarix are still incompletely 
understood but likely are multi-factorial. First, Rotavirus immunity is polygenic as it 
induces neutralizing antibodies to VP7 and VP4 and non-neutralizing antibodies to other 
structural viral proteins VP1, VP2 and VP6, and to nonstructural viral proteins NSP2, 
NSP5, and the viral enterotoxin NSP4. Each viral protein-specific antibody might play a 
protective role. Second, different genotypes of Rotavirus share neutralization epitopes on 
VP4 and VP7, which could induce cross-reactive neutralizing antibody and protection. 
Besides, other mechanisms, such as T cell-mediated immunity or other host factors, may 
contribute to cross-protection [117]. 
5.4. LIMITATIONS OF THE STUDY 
Our study was just included the sentinel surveillance in Southern Vietnam, which 
may not represent the whole country. All of the pediatric patients with AGE in this study 
were hospitalized, suggesting that their symptoms were more severe than those of non-
hospitalized cases. Since we did not collect samples from non-hospitalized children, it is 
difficult to draw any conclusion about the severity of Rotavirus-associated AGE among 
children in the community. Further studies involving both hospitalized and non-
hospitalized cases of Rotavirus gastroenteritis are needed. 
5.5. FURTHER RESEARCH 
Regarding the overall prevalence estimates of particular Rotavirus genotypes, the 
problem of sampling bias should not be underrated. The Rotarix VE against G3P[8] 
predominant genotype was considerable high; however, with the dramatic genotyping shift 
being identified in this study, there is still necessary to consider the strains of the 
recommended vaccine, which will be used in the National Immunization Program in the 
near future. Continued surveillance is needed to monitor changes in Rotavirus 
epidemiology before and after vaccine introduction. In addition to monitoring genotypes, 
whole genomic characterization of circulating Rotavirus strains will help assess whether 






Our study suggested that Rotavirus infection was still a significant cause of acute 
watery diarrhea among hospitalized children younger than five years old in Vietnam. 
Rotavirus positivity varied seasonally with the peak rates during the dry season of 
November to April.  
Rotavirus AGE was more likely to be found in children ≥ 6 months. In terms of 
clinical features, it was more severe and less likely to be treated with antibiotics than the 
negative group. 
We also observed an enormous genotyping shift from 2013 to 2018: G3P[8] 
became predominant while G1P[8] considerably dropped. There is a need to consider the 
recommended vaccine to use in the National Immunization Program within the dramatic 
genotyping shift situation.  
In the context of low vaccine proportion, among children ≥ 6 months, getting a full 
schedule of Rotavirus vaccine in general and Rotarix, in particular, had vaccine 
effectiveness against Rotavirus AGE at 82.34% and 85.90%, respectively. Noticeably, 
Rotarix VE for G3P[8] was 88.35% (95%CI: 52.50%-97.14%). Whole genomic 
characterization of circulating Rotavirus strains before and after vaccine introduction will 
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ROTAVIRUS REPORTING FORM 
Form 27/2012-TCMR 
 
Suspected case: A child 0-59 months has acute (<14 days) watery diarrhea, defined as 
three or more in a 24-hour period. 
PART I. FOR HOSPITAL 
A. General information 
1. Case ID:           
2. Hospital name: ……..………………………..………….                               
3. Medical record number: …………………… Date of hospital amidssion: 
……./……./… 
4. Patient's name: ………………………………………Gender:  * Male     * Female 
5. Date of birth:  _____/___/_____     
6. If date of birth is unknown, age of the child:  ....... years old, or  …… months old, or 
…… days old. 
7. Address:  Number/ Village……Ward/ Commune:…… District:……… 
Province:…… 
8. Contact number: ……………………………………… 
B. History and treatment 
9. Did the child vaccinated Rotavirus vaccine?  * Yes          * No              
10. Date of vaccinated: 1st doset___/___/___2nd dose___/____/___ 3rd 
dose___/____/____  
11. Source of information:       * Immunization card  * Asking        * Unknown 
12. Had diarrhea in: …… days. Maximum number of diarrhea in a 24-hour 
period:………. 
13. Had vomitingin: ……days. Maximum number of vomitted in a 24-hour period: .…… 
14. Dehydration level:      * No            * Some dehydration        * Severe dehydration 
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15. Had treatment: * ORS      * IV      * Antibiotic 
               * Probiotic    * Others: …………………………....  * Unknown 
16. Chil point of entry:  * Emergency   * OPD   * Gastroenterology  * Others 
17. Status of discharge: * Alive     * Dead (date of daed:___/___/_____)  * Unknown 
                               Date of discharge:___/___/__ 
18. Stool sample collected:     * Yes                * No      * Unknown 
                          If yes, date of stool sample collected:_____/_____/_______ 
19. Other comments: …………………………………………………………………… 
 Date of report……/…../……… 
                                     Investgator 
                                    (Name, Signiture) 
PART II. FOR PASTEUR INSTITUTE                                                   
1. Laboratory number: ………………………………      
2. Date of stool sample received: ____/____/_______    
3. Stool characteristic: * Watery  * Non watery  * Bloody  * 
Other....................................... 
4. Stool codition: * Good  (No spillage, cold)  * Warm when touch the sample  * Broken  
5. Stool quantity:   * Sufficient     * Unsufficient * 
Other........................................................ 
6. ELISA (EIA) resul:    * Positive   * Negative   * Suspected  * Didn't make the test 
Date of having result:____/___/_____               Date of reporting 
result:____/___/_____ 
7. Genotyping:  G type ___  P type ___  Unknown: * G type   * P type  * Both G & P 
Date of having genotyping result:___/___/___ 
Date of reporting genotyping result:___/___/___ 
8. Other comments: ……………………………………………………………  
                                                       Laboratory                                 
 (Name, Signiture) 
